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1.1 MEGAKARYOCYTOPOIESIS 
 
 
1.1.1 HAEMATOPOIESIS 
Blood cells are traditionally categorized into two separate lineages: lymphoid and myeloid 
lineage. The lymphoid lineage consists of T, B, and NK cells, which carry out adaptive and 
innate immune responses. The myeloid lineage includes granulocytes (neutrophils, 
eosinophils, mast cells, and basophils), monocytes, erythrocytes, megakaryocytes and 
platelets. Because these mature blood cells are predominantly short lived, ranging from 
few hours for granulocytes to a couple of weeks for erythrocytes, it is demand a continued 
process through immature cells become differentiated blood cells which are functionally 
competent.  
This process is named hematopoiesis, it takes place primarily in the bone marrow, and it is 
organized as a cellular hierarchy with a common precursor, the hematopoietic stem cell 
(HSC), at the apex, terminally differentiated cells on the bottom, and a series of progenitor 
cell intermediates that undergo a gradual fate restriction to assume the identity of a mature 
blood cell (Figure 1.1.1)(Doulatov S et al. 2012). 
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Figura 1.1.1. The diagram summarize human haematopoiesis showing lineage relationship between the 
different subtypes, from HSC, to mature cells; the main surface markers are displayed. (Doulatov S et 
al. 2012) 
 
In human bone marrow only 1 in 10
6
 cells is a transplantable HSC (Wang et al. 1997), and 
the first marker used to identify this population is CD34 (Civin et al. 1984), actually, the 
generally accepted phenotype of human HSCs is CD34
+
CD38
–
Thy1
+
CD45
–
, emerged over 
the past decades (Bhatia et al. 1997; Conneally et al. 1997; Lansdorp et al. 1990). HSCs 
are critical for lifelong blood production and are uniquely defined by their capacity to 
durably self-renew, or generate daughter stem cells, while still contributing to the pool of 
differentiating cells. The multi potent progenitor (MPP), derived from HSC, shows high 
proliferative and self-renewal capacity and starts the differentiation process in 
hematopoiesis leading to oligopotent and later on to lineage-committed progenitors with a 
diminished proliferation but increased differentiation (Notta et al. 2011). The 
contemporary model of hematopoiesis assumes that the decision for differentiation into the 
lymphoid/myeloid or megakaryocyte/erythrocyte lineages probably occurs very early in 
hematopoiesis. Several studies have demonstrated that multipotent progenitors like the 
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lymphoid-primed multipotent progenitor (LMPP) retain only minor 
megakaryocyte/erythrocyte lineage potential, whereas the vast majority of progenitors 
appears to be committed to the granulocyte/monocyte as well as the lymphoid lineage. 
In the next step of ongoing differentiation oligopotent progenitors with differentiation 
capacity for several hematopoietic lineages develop from an ancestor, the common 
lymphoid progenitor (CLP) and the common myeloid progenitor (CMP). The CLP is the 
earliest population in the lineage-negative fraction that upregulates the receptor for 
interleukin 7 (IL-7), an essential cytokine for T and B cell development. Furthermore, the 
CLP carries differentiation potential for all types of lymphoid cells including B cells, T 
cells and NK cells.  
The megakaryocyte-erythrocyte progenitor (MEP) is restricted to megakaryocytes and 
erythrocytes. 
Still a matter of dispute is the dendritic cell (DC) development, because DC mainly are the 
progeny of GMP, but can also be generated from lymphoid progenitors such as CLP and 
pro T cells under certain conditions. However, the majority of plasmacytoid DC (pDC) and 
conventional or myeloid DC (mDC) develop successively by several commitment steps 
downstream of the GMP in the bone marrow. The first step is the development of the 
monocyte/macrophage and DC precursor (MDP) out of the GMP that has lost 
differentiation potential for granulocytes. Further differentiation of MDP, which is 
accompanied by the loss of monocyte potential, leads to the common DC precursor (CDP) 
that can only give rise to pDC and mDC. 
Besides the characterization of MDP and CDP by several studies, further progenitor 
populations for eosinophils, basophils and mast cells have been isolated downstream of the 
GMP and their position in the hematopoietic hierarchy is depicted.   
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Moreover, the monopotent megakaryocyte lineage-committed progenitor (MKP) and 
erythroid progenitor (EP) have been described downstream of the MEP.  
Only for the monocyte/macrophage lineage and the neutrophil granulocytes, a putative 
committed precursor downstream of the GMP has not been identified to date.  
With regard to lymphoid development one committed precursor downstream of the CLP is 
the bipotent T/NK cell progenitor that resides in the bone marrow and is able to generate 
thymic- and bone marrow-dependent NK cells as well as T cells. 
Lineage commitment is to a large part mediated by small soluble extracellular protein 
cytokines or growth factors, but also by other extracellular factors, including direct cell-
cell or cell-extracellular matrix interactions. Alternatively, it could be induced by intrinsic 
mechanisms, such as the stochastic up-regulation of transcription factors, or other 
regulatory molecules, such as microRNAs (Laiosa CV et al. 2006).  
Whether cytokines/growth factors can actively instruct the lineage choice of hematopoietic 
stem and progenitor cells or merely create a selective environment in which numbers of 
intrinsically committed cells are amplified by receiving survival and proliferation signals 
has been disputed for many years. Activation of the receptors leads to common 
downstream signaling events and ultimately to lineage-characteristic gene expression, 
depending on the intracellular context of the target cell. It is proved that most cytokine 
receptors activate very similar if not essentially identical downstream signaling pathways 
and, at the same time, cytokines can have pleiotropic effects on different cell types and 
even different maturation stages within the identical lineage (Endele et al. 2012).  
Defining the exact cocktail of cytokines required to commit HSC into lymphoid cellular 
subtypes is complex because several Interleukins (IL) are required: the most important and 
better defined cytokines involved in this process are IL-2, 4, 7, 15. IL-7 is fundamental in 
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the early lymphoid commitment and, with IL-2, it commits lymphoid progenitors to the T 
lineage; IL-4 and IL-15 are needed to commit lymphoid precursors to B and NK lineages, 
respectively. 
Instead, stem cell factor (SCF) and Thrombopoietin (TPO) are important cytokines that 
enhance proliferation and of HSCs and their early commitment in CMPs; with IL-3, these 
cytokines also drive CMPs to differentiate into MEPs, which will be committed to the 
erythrocytic lineage in presence of erythropoietin (EPO) or to the megakaryocytic lineage 
in presence of TPO. On the other hand, granulo-monocyte colony stimulating factor (GM-
CSF) pushes CMPs to differentiate in GMPs;  monocyte colony stimulating factor (M-
CSF) is needed to differentiate GMPs into monocytes while granulocytes colony 
stimulating factor (G-CSF) to differentiate GMPs into granulocytes (Kaushansky K et al. 
2006). 
 
1.1.2 MEGAKARYOCYTOPOIESIS 
Megakaryocytopiesis is the process by which a hematopoietic stem cell differentiates into 
a large progenitor cell in the bone marrow, called megakaryocyte (MK), which eventually 
release platelets by the extension of long, cytoplasmic branching processes, designated 
proplatelets, into the circulation. 
 
Regulation of megakaryocytopoiesis 
MKs develop from haematopoietic stem cells in the bone marrow and the process of 
differentiation is mainly regulated by thrombopoietin (TPO). 
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The discovery of thrombopoeitin (TPO), and its MK-specific receptor c-Mpl 
revolutionized the field of MK and platelet biology. In 1994, several groups discovered 
and cloned c-Mpl, the receptor that promotes the growth and development of MKs from 
their haematopoietic stem cell precursors (Bartley TD et al. 1994; Kaushansky K et al. 
1994; Kuter DJ et al. 1994; Lok S et al. 1994; de Sauvage SJ et al. 1994; Sohma Y et al. 
1994; Wendling F et al. 1994). This discovery facilitated development of in vitro cell 
culture systems that reconstituted MK differentiation, proplatelet extension and platelet 
production, and allowed study of the mechanisms that regulate these processes (Cramer 
EM et al, 1997; Lecine P et al, 1998). In vitro studies revealed that binding of TPO to c-
Mpl results in dimerization of the receptor and activation of a number of downstream 
signalling pathways, including the phosphatidyli- nositide 3-kinase (PI3K), Akt, MAPK 
and ERK1/ERK2 path- ways (Kaushansky K. 2005).  
TPO was emerged as the primary regulator of thrombopoiesis. It has been demonstrated 
that elimination of either c-Mpl or TPO leads to severe thrombocytopenia, due to reduced 
MK progenitors and mature MKs as well as reduced maturation in the remaining MKs 
(Solar GP et al. 1998). Interestingly, in most cases of thrombocytopenia, plasma TPO 
concentration varies inversely with platelet number (Nichol JL et al. 1995). This is due to 
an autoregulatory loop. Platelets have c-Mpl receptors that bind to and remove TPO from 
plasma, and as platelet numbers rise, more TPO is removed from circulation, driving TPO 
levels down. Conversely, in thrombocytopenic states there are fewer platelets to adsorb 
TPO, allowing levels to rise and drive increased thrombopoiesis. While at first seemingly 
counterintuitive, this regulatory loop explains why high blood platelet levels are associated 
with low TPO levels, and vice versa. 
More recently, it has been shown that TPO not only drives proliferation and maturation of 
MKs but also other bone marrow-derived progenitor cells, in particular TPO act as a 
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moderator of the osteoblastic haematopoietic stem cell niche expansion (Olson TS et al. 
2013). After clinical stem cell transplantation, haematopoietic stem cells preferentially 
engraft in specialized areas of bone marrow known as haematopoietic stem cell niches. 
Olson et al. performed radioablative conditioning in mice, and showed that host MKs are 
subsequently recruited to the haematopoietic stem cell niche, where they stimulate 
expansion and facilitate stem cell engraftment after transplantation. Interestingly, the 
migration of MKs to the niche is dependent on TPO signalling through the c-Mpl receptor 
on MKs. Likewise, inhibition of c-Mpl-dependent MK migration and function results in 
significantly decreased donor stem cell engraftment in murine transplantation assays 
(Olson TS et al. 2013). This is consistent with older data showing that TPO-overexpressing 
mice develop a myeloproliferative phenotype similar to idiopathic myelofibrosis described 
in humans, with symptoms including thrombocytosis, leucocytosis and bone marrow 
myelofibrosis (Yan XQ et al. 1996; Villeval JL et al. 1997).  
Still undefined, however, is the precise cellular and molecular pathways by which TPO 
modulates the bone marrow environment in a way that enhances stem cell proliferation and 
maturation. 
Other cytokines, in addition to TPO, are involved in MKs differentiation. In particular IL-
3, a cytokine produced by both mast cells and T lymphocytes, can independently stimulate 
the early stages of megakaryocyte development up to the endomitotic phase (Segal GM et 
al. 1988; Yang YC et al. 1986). Kit ligand, also known as stem cell factor, Cytokines such 
as IL-6, IL-11, and stem cell factors, also regulate stages of megakaryocyte development at 
multiple levels but appear to function only in concert with TPO or IL-3 (Flanagan JG, 
Leder P. 1990; Briddell RA et al. 1991). 
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Megakaryocyte commitment 
MKs develop from haematopoietic stem cells that reside mainly in the bone marrow, but 
are also found in the yolk sac, fetal liver and spleen in early development (Long MW et al. 
1982; Ogawa M.1993). Various classification schemes based on morphological features, 
histochemical staining, and biochemical markers have been used to categorize different 
stages of megakaryocyte development. In general, three types of morphologies can be 
identified in bone marrow (Figure 1.1.2) 
.  
Figura 1.1.2 A schematic representation of megakaryocyte commitment. (Italiano JE and Hartwing JH. 
Platelets 3
rd
 edition). 
 
The promegakaryoblast is the first recognizable megakaryocyte precursor. The 
megakaryoblast, or stage I megakaryocyte, is a more mature cell that has a distinct 
morphology (Long MW et al. 1992).
 
The megakaryoblast has a kidney-shaped nucleus with 
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two sets of chromosomes (4N). It is 10 to 50μm in diameter and appears intensely 
basophilic in Romanovsky-stained marrow preparations as a result of the large quantity of 
ribosomes, although the cytoplasm at this stage lacks granules. The megakaryoblast 
displays blebbing of the plasma membrane, a high nuclear-to-cytoplasmic ratio and, in 
rodents, is acetylcholinesterase-positive. The promegakaryocyte, or stage II 
megakaryocyte, is 20 to 80μm in diameter with a polychromatic cytoplasm. The cytoplasm 
of the promegakaryocyte is less basophilic than the megakaryoblast and contains 
developing granules. 
In humans, MK progenitors have been characterized by clusters of differentiation markers 
on their surface also present in other hematopoietic progenitors, such as the CD34, CD31, 
and the CD133. The expression of HLA-DR enables BFU-MK (HLA-DR
low
) to be 
distinguished from CFU-MK (HLA-DR
high
) (Briddell RA, et al. 1989). Most studies have 
focused on the main platelet glycoproteins, the GPIIb/IIIa (aIIbb3 integrin or CD41b) and 
the GPIb complex (GPIba, GPIbb, GPIX and GPV or CD42a, b, c and d) (Mazur EM et al. 
1981; Vinci G et al. 1984). CD41a (GPIIb) or CD41b (GPIIb/IIIa complex) appear 
relatively specific for the MK lineage, especially in adults, although mast cells can express 
these integrins (Kirshenbaum AS  et al. 2005). CD41 is present on a small fraction of 
marrow CD34
+
 cells (about 3%). These CD34
+
 CD41
+
 cells are enriched in MK 
progenitors, but they do not contain all the CFU-MK. CD41 expression precedes the 
detection of other major platelet proteins including CD42. However, CD42 is present on a 
fraction of CD34
+
 CD41
+
 cells (Debili N et al.1992). Thus, CD34
+
 CD41
+
 CD42
-
 
cells 
correspond to true CFU-MK whereas CD34
+
 CD41
+
 CD42
+ 
cells give rise to single MKs 
or clusters of less than 4 MKs. The surface expression of CD42 corresponds to a late 
differentiation step and is associated with a marked increase in the expression of Mpl, 
GPVI (collagen receptor), the a2b1 integrin (collagen receptor), CD36 and in the detection 
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of proteins contained in the a granules, such as PF4 or vWF. Thereafter, expression of 
these different platelet proteins markedly increases whereas the CD34 antigen disappears 
during the endomitotic process (Figure 1.1.3) (Chang Y et al. 2007). 
 
Figure 1.1.3. Expression of differentiation markers along the human megakaryocytic differentiation. 
(Chang Y et al. 2007) 
During development, MKs increase in size, became polyploid and full of granules, expand 
their cytoplasmic content of cytoskeletal proteins and develop a highly invaginated 
membrane system. 
 
Endomytosis and polyploidization 
Endomitosis in MKs is a TPO-dependent process by which MKs become polyploid 
through cycles of DNA replication without cell division (Ebbe S. 1976; Gurney AL et al. 
1994). During their life cycle, MKs first undergo a proliferative 2n stage in which their 
progression through the cell cycle is identical to other haematopoietic cells. Following 
which, MKs begin endomitosis and accumulate a DNA content of 4n, 8n, 16n, 32n, 64n, 
and even 128n in a single polylobulated nucleus before proceeding with their final 
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maturation and subsequent proplatelet formation (Zimmet J, Ravid K. 2000). Although the 
number of endomitotic cycles can range from two to six, the majority of megakaryocytes 
undergo three endomitotic cycles to obtain a DNA content of 16N. 
Endomitosis does not result from a prematurely terminated mitosis (Raslova H et al. 2003; 
Nagata Y et al. 1997; Vitrat N et al 1998) (Figure 1.1.4). 
 
Figure 1.1.4. A schematic representation of endomitotic cell cycle in megakaryocytes. (Ravid et al. 
2002) 
 
Megakaryocyte progenitors initiate the cycle and undergo a short G1 phase, a typical S 
phase for DNA synthesis, a short G2 phase, followed by endomitosis (Odell T et al. 1968). 
Megakaryocytes begin the mitotic cycle and proceed from prophase to anaphase A, but do 
not enter anaphase B or telophase or undergo cytokinesis. The nuclear envelope breaks 
down and an abnormal spherical mitotic spindle forms, each spindle attaches chromosomes 
that align to a position equidistant from the spindle poles (metaphase). Sister chromatids 
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segregate and begin to move toward their respective poles (anaphase A). However, the 
spindle poles fail to move apart and do not undergo the separation typically observed 
during anaphase B. Individual chromatids are not moved to the poles, and subsequently a 
nuclear envelope reassembles around the entire set of sister chromatids, forming a single 
enlarged, but lobed, nucleus with multiple chromosome copies. The cell then skips 
telophase and cytokinesis to enter G1. This failure to separate sets of daughter 
chromosomes fully may prevent the formation of a nuclear envelope around each 
individual set of chromosomes (Nagata Y et al. 1997; Vitrat N et al 1998).
 
Much work has focused on identifying the signals that regulate polyploidization, 
highlighting a critical role for mitosis promoting factor (MPF) activity, a multiprotein 
complex consisting of Cdc2 and cyclin B (Wang Z et al. 1995; Gu XF et al. 1993), Rho 
family (Geddis AE, Kaushansky K. 2006), and protein-tyrosine phosphatases Shp1 and 
Shp2 (Mazharian A et al. 2013), however a complete and definitive description of 
endomitosis regulator is not currently available. 
Polyploidization is essential for efficient platelet production. It is theorized that MKs are 
polyploid in order to support cytoplasmic maturation characterized by a great production 
of mRNA and proteins that are packaged into granules and platelets and by a formation of 
invaginated membrane system (IMS) generation from which proplatelets derive  (Zimmet 
J, Ravid K. 2000; Machlus KR, Italiano JE. 2013). 
Cytoplasmic maturation 
After the process of endomitosis is completed, the megakaryocyte begins a maturation 
stage in which the cytoplasm rapidly fills with platelet-specific proteins, organelles, 
granules and membrane systems that will ultimately be subdivided and packaged into 
platelets. 
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In the MK, granules are derived from the budding of small vesicles containing granule 
cargo from the trans-Golgi network (Blair P, Flaumenhaft R. 2009). Vesicles budding 
from the trans-Golgi network may be delivered directly to multivesicular bodies, where 
proteins are sorted and eventually pack- aged into granules (Heijnen HF et al. 1998; 
Youssefian T, Cramer EM. 2000). Organelles and granules are then individually 
transported from the MK cell body, along the proplatelet shaft where they move 
bidirectionally until they are captured at proplatelet tips (Richardson JL et al. 2005). 
The most abundant are α granules, which contain proteins essential for platelet adhesion 
during vascular repair. These granules are typically 200 to 500 nm in diameter and have 
spherical shapes with a dark central core. They are present in early-stage megakaryocytic 
(Jones OP. 1960)
 
 and they acquire their molecular contents both from endogenous protein 
synthesis and by uptake and packaging of plasma proteins by receptor-mediated 
endocytosis and pinocytosis (Handagama P et al. 1987).
 
Endogenously synthesized 
proteins such as platelet factor 4, β-thromboglobulin, and von Willebrand factor are 
detected in megakaryocytes before endocytosed proteins such as fibrinogen. In addition, 
synthesized proteins predominate in the juxtanuclear Golgi area, whereas endocytosed 
proteins are localized in the peripheral regions of the cell (de Larouziere V et al. 1998). It 
has been well documented that uptake and delivery of fibrinogen to α granules is mediated 
by integrin αIIβ3 (Coller BS et al. 1991; Handagama P et al. 1993; Handagama P et al. 
1993-2).
 
Several membrane proteins critical to platelet function are also packaged into α 
granules, including integrin αIIbβ3, P-selectin (CD62P), and CD36. MKs also contain 
dense granules, approximately 250 nm in size, identified in electron micrographs by virtue 
of their electron-dense cores, contain a variety of hemostatically active substances that are 
released upon platelet activation, including serotonin, catecholamines, ADP, adenosine 5
’
-
triphosphate (ATP), and calcium (Youssefian T et al. 2000). 
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The maturation of MKs is characterized by the progressive formation of an elaborate 
membrane system that is continuous with the plasma membrane and permeates the 
cytoplasm. Originally, the IMS was called the demarcation membrane system (DMS) 
because it was thought to divide, or ‘demarcate,’ the MK cytoplasm into small territories 
from which platelets were formed (Behnke O. 1969; Radley JM, Haller CJ. 1982). 
However, since establishing the proplatelet model of platelet release, it is more accurately 
referred to as the IMS to reflect its unique characteristics; the IMS is derived from the 
plasma membrane, retains contact with the extracellular environment and functions as a 
membrane reservoir for proplatelet formation (Behnke O. 1969; Nakao K, Angrist AA. 
1968). The IMS has also been proposed to mature into the open canalicular system (OCS) 
of mature platelet, which functions as a channel for the secretion of granules contents 
(Nakao K, Angrist AA. 1968). 
 
Platelet formation  
Although it has been universally accepted that platelets derive from megakaryocytes, the 
mechanisms by which platelets are formed and released by these precursor cells are still 
largely unclear and several models of platelet formation have been proposed. (Figure 
1.1.5). 
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Figure1.1.5. Mechanisms proposed for platelet production (Italiano JE and Hartwing JH. Platelets 3
rd
 
edition) 
 
The first model is the cytoplasmic fragmentation via the DMS. Microscopists recognized 
that maturing megakaryocytes became filled with membranes and platelet-specific 
organelles and postulated that these membranes formed a system that defined territories or 
fields for developing platelets (Shaklai M, Tavassoli M. 1978).
 
Release of individual 
platelets was proposed to occur by a massive fragmentation of the megakaryocyte 
cytoplasm along DMS fracture lines residing between these fields. The DMS model 
predicts that platelets form through an extensive internal membrane reorganization process 
(Kosaki G. 2005). However this model has lost support because of several inconsistent 
observations. For example, if platelets are delineated within the megakaryocyte cytoplasm 
by the DMS, then platelet fields should exhibit structural characteristics of platelets, which 
is not the case (Radley J, Hatshorm M. 1987).
 
Platelet territories within the megakaryocyte 
cytoplasm lack marginal microtubule coils, the most characteristic feature of resting 
platelet structure. In addition, there are no studies directly demonstrating that platelet fields 
shatter into mature, functional platelets. 
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According to the second model, named platelet budding, platelets pinch off from blebs 
protruded at the megakaryocyte periphery. Examination of these structures by thin-section 
electron microscopy, however, revealed that these blebs did not contain platelet organelles, 
an observation inconsistent with the concept of platelet budding as a mechanism for 
platelet release (Djaldetti M et al. 1979; Ihzumi T et al 1977). 
Actually the most accreditate theory for platelet formation is the proplatelet  model. 
Proplatelet model 
Mature MKs extend long, branching processes called proplatelets into the sinusoidal blood 
vessels of the bone marrow. The process commences at a single site on the MK plasma 
membrane. From this region, a pseudopod forms, elongates, and tapers into a tubule with 
an average diameter of 2– 4 um, called the proplatelet shaft. Proplatelets function as the 
assembly lines of platelet production, and are comprised of platelet-sized swellings in 
tandem arrays along the shaft (Italiano JE et al. 1999). The multi-lobed nucleus remains in 
the MK cell body as the rest of the MK is transformed into proplatelets. After the entirety 
of the MK cell body is converted into proplatelets, the nucleus is extruded and degraded 
(Figure 1.1.6 and Figure 1.1.7). 
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Figura 1.1.6. Video-enhanced light microscopy of mouse megakaryocyte forming proplatelet in vitro 
(Italiano JE and Hartwing JH. Platelets 3
rd
 edition). 
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Figure 1.1.7. Proplatelet process (Patel SR et al.2005). 
 
Proplatelet formation is dependent on the function of microubules. Microtubules, polymers 
assembled from dimers of alpha and beta tubulin, are the major components of the machine 
that drive proplatelet extension. Visualization of the microtubule cytoskeletons of 
proplatelet-producing MKs provides insights into how microtubules power platelet 
production. The microtubule cytoskeleton in MKs undergoes a remodelling during 
proplatelet production. (Figure 1.1.8). 
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Figure 1.1.8. Propatelet model detailing some of the cytoskeletal mechanisms of platelet biogenesis 
(Italiano JE and Hartwing JH. Platelet 3
rd
 edition) 
 
In immature megakaryocytes, that have not formed proplatelets, microtubules extend out 
from the cell centre to the cortex. As thick pseudopodia develop during the initial stages of 
proplatelet formation, cortical microtubules organize into thick bundles situated beneath 
the plasma membrane of these processes. When pseudopodia begin to elongate (at an 
average rate of 0.85 um/min), microtubules form thick arrays that line the entire length of 
the proplatelets (Italiano JE et al. 1999). The microtubule bundles are thickest in the 
region of the proplatelet near the body of the MK, but narrow to bundles of 5–10 
microtubules near proplatelet tips. The distal end of each proplatelet always has a 
microtubule bundle that loops just beneath the plasma membrane and re-enters the shaft to 
form a teardrop-shaped or tennis racket-shaped structure. Because microtubule coils 
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similar to those observed in blood platelets are detected only at the ends of proplatelets and 
not within the platelet-size beads found along the length of proplatelets, mature platelets 
are formed only at the tips of proplatelets (Italiano JE et al. 1999). Moreover, the ends of 
proplatelets are amplified in a dynamic process that repeatedly bends and bifurcates the 
proplatelet shaft (Italiano JE et al 1999).
 
End amplification initiates when a proplatelet 
shaft is bent into a sharp kink that then folds back on itself, forming a loop in the 
microtubule bundle. The new loop eventually elongates, forming a new proplatelet shaft 
branching from the side of the original proplatelet. Loops lead the proplatelet tip and 
define the site where nascent platelets will assemble and where platelet-specific contents 
are trafficked. In marked difference from the microtubule-based motor that elongates 
proplatelets, actin-based force is used to bend the proplatelet in end amplification.  
In addition to playing a crucial role in proplatelet elongation, the microtubules lining the 
shafts of proplatelets serve a second important function—tracks for the transport of 
membrane, organelles, and granules into proplatelets and assembling platelets at 
proplatelet ends. Individual organelles are sent from the cell body into the proplatelets, 
where they move bidirectionally until they are captured at proplatelet ends (Kelley MJ et 
al. 2000). 
The final step of platelet formation is represented by proplatelets extension into bone 
marrow vascular sinusoids, where they are released and enter the bloodstream (Figure 
1.1.9) 
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Figure 1.1.9. Megakaryocyte protruding proplatelets into bone marrow vessel. (Geddis AE et al. 2007)  
 
Notably, it has been observed that these enucleate fragments typically exceed platelet 
dimensions, suggesting that platelet morphogenesis continues in the circulation (Junt T et 
al. 2007). In line with these observations, Thon and co-workers, have recently identified a 
previously unrecognized intermediate stage in platelet formation and release, which they 
termed the preplatelet (Thon JN et al, 2010).
 
Preplatelets, which appear as “giant 
platelets,” are defined as discoid cells (3-10 microns) that retain the capacity to convert 
into barbell-shaped proplatelets and undergo fission into platelets. (Figure 1.1.10) 
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Figure 1.1.10. Proplatelet fission model of platelet release (Thon JL et al. 2010) 
 
1.1.3 BCL-2 FAMILY IN MEGAKARYOCYTOPOIESIS 
There is an ongoing debate about the role of apoptosis in platelet formation, and 
considerable evidence has been accumulated suggesting that apoptosis is necessary for 
MKs to start proplatelet formation (De Botton et al, 2002; Clarke et al, 2003). 
Apoptosis refers to two convergent pathways of programmed cell death: intrinsic and 
extrinsic (Youle & Strasser, 2008) (Figure 1.1.11). 
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Figure 1.1.11. A schematic representation of the two pathways of apoptosis. (Kile BT. 2014) 
 
The critical regulators and effectors of the former are proteins of the BCL2 family, which 
are characterized by the presence of one or more BCL2 homology (BH) domains. They are 
divided into three groups. The first comprises the multi-domain killers BAK1 and BAX, 
which are the essential effectors of the intrinsic pathway. The second group are the pro-
survival proteins (BCL2, BCL-XL, BCL2L2, MCL1 and BCL2A1), whose function is to 
prevent the activation of BAK1 and BAX. While the precise mechanisms are still being 
clarified, it is believed they achieve this by physically restraining BAK1 and BAX and by 
sequestering a third group of pro- apoptotic BCL2 family members known as ‘BH3-only’ 
proteins (BIM (BCL2L11), BID, BAD, PUMA (BBC3), NOXA (PMAIP1), BMF, BIK 
and HRK). In a healthy cell, BCL2 family pro-survival activity is sufficient to keep BAK1 
and BAX in check. Apoptotic signals, such as DNA damage, trigger the BH3-only 
proteins, either by transcriptional upregulation or post-translational modification, thereby 
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allowing them to overwhelm the function of the pro-survival proteins and activate BAK1 
and BAX. This is thought to be the result of BH3-only proteins binding to and inhibiting 
pro-survivals, but also by directly binding and activating BAK1 and BAX (Willis SN et al. 
2007; Ren D et al. 2010). Once unleashed, the latter oligomerize and induce mitochondrial 
outer membrane permeabilization (MOMP), facilitating the efflux of apoptogenic factors, 
such as cytochrome c and SMAC (DIABLO), into the cytoplasm, and eventually leading to 
the dissipation of mitochondrial potential. Once MOMP has occurred, the apoptotic 
caspase cascade is engaged, beginning with the ‘initiator’, or ‘apical’ caspase, caspase-9. 
Together with APAF1 and cytochrome c, the inactive caspase-9 zymogen is recruited to 
form the apoptosome complex, the function of which is to proteolytically activate caspase-
9. Active caspase-9 then triggers the rest of the caspase cascade, culminating in the 
activation of the ‘effector’ caspases, caspase-3 and caspase-7. Caspases are the 
executioners of the intrinsic apoptosis pathway, mediating many of the hallmarks of 
apoptosis, such as DNA fragmentation, phosphatidylserine (PS) exposure and membrane 
blebbing. The other apoptotic pathway, the extrinsic, is activated by ligands binding to cell 
surface death receptors that belong to the tumour necrosis factor (TNF) receptor family, 
such as FAS or TNF receptor-1 (TNFR1). Once activated, the adap- tor protein FAS-
associated death domain (FADD) and caspase-8 are recruited to the receptor complex. 
Caspase-8 is the essential mediator of the extrinsic apoptosis pathway. Following 
proteolytic cleavage, the activated form of caspase-8 directly triggers activation of 
caspase-3/7. In so-called Type I cells, such as lymphocytes, this is sufficient to induce 
death (Scaffidi C et al. 1998). In Type 2 cells, such as hepatocytes, the additional 
recruitment of the intrinsic pathway is required to induce killing. This is achieved via 
caspase-8-mediated activation of the BH3-only protein BID, which then triggers the 
activation of BAK1 and BAX (Yin MB et al. 1999; Jost PJ et al. 2009). 
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In the last twenty years, the identification of thrombopoietin (TPO) and development of 
primary megakaryocyte culture systems led to the observation that peak platelet production 
by mature megakaryocytes ‘corresponded to the onset of apoptosis’ (Zauli G et al. 1997). 
When mice lacking the pro-death BH3-only protein BIM (Bouillet P et al. 1999), or 
overexpressing pro-survival BCL2 were found to be thrombocytopenic, the idea that 
megakaryocytes might undergo apoptosis deliberately in order to facilitate platelet 
shedding was born (Ogilvy S et al. 1999). 
Seminal work by Debili and colleagues cemented this hypothesis (De Botton S et al. 2002). 
They reported the presence of active apoptotic caspases in the cytoplasm of cultured 
primary human CD34
+
-derived megakaryocytes, and showedhat proplatelet formation was 
impaired in the presence of the fluoromethylketone caspase inhibitors Z-VAD.fmk, Z-
LEDH.fmk or Z-DEVD.fmk. Moreover, transgenic megakaryocytes expressing BCL-XL 
under the control of the Platelet Factor 4 (PF4) promoter, produce fewer proplatelets in 
culture (Kaluzhny Y et al. 2002). 
Collectively, these data point to a productive role for the intrinsic apoptosis pathway in 
platelet production and, in particular, Bcl-xL expression is critical to allow the survival of 
the cells during the early endomitotic phase of megakaryocytic differentiation, but it must 
decrease to allow the platelet release process to happen, which can be considered a peculiar 
and productive apoptotic-like process (Kile BT. 2014). 
In recent years, the role of the intrinsic apoptosis pathway in megakaryocytes has 
been explored in detail, through studies conducted in genetically modified mice.  
Spurred on by the data linking the pathway to the regulation of platelet life span, several 
groups have examined the requirement for BCL2 family proteins and apoptotic caspases in 
megakaryocyte life and death. The results to date clearly indicate that megakaryocytes, like 
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their anucleate progeny, possess a fully functional intrinsic apoptosis pathway. In addition 
to BCL-XL, megakaryocyte growth and development requires MCL1 (Josefsson et al. 
2011; Debrincat et al. 2012; Kodama et al. 2012). Megakaryocyte-specific deletion of 
BCL-XL results in severe thrombocytopenia, a reflection not only of dramatically reduced 
platelet life span, but aberrant platelet shedding by dying megakaryocytes (Josefsson EC et 
al. 2011). It appears that at least in mice, megakaryocytes become dependent on BCL-XL 
just at the point at which they are ready to produce proplatelets. While BCL-XL-deficient 
megakaryocytes develop normally, they are unable to form proplatelets in vitro, and 
manifest striking ultrastructural defects in vivo, with large vacuolated fragments of 
cytoplasm being sloughed off into the sinusoids. Loss of both MCL1 and BCL-XL results 
in a failure of megakaryopoiesis, systemic haemorrhage and embryonic lethality, 
indicating that the combined functions of both pro-survivals are required for 
megakaryocyte growth and development (Debrincat MA et al. 2012; Kodama T et al. 
2012). If their role is to prevent the activation of the intrinsic apoptosis pathway, then it 
would be expected that deletion of BAK1 and BAX would completely rescue the defects 
caused by loss of MCL1 and BCL-XL, and this is indeed the case: quadruple MCL1/BCL- 
XL/BAK1/BAX knockout mice are healthy and exhibit normal megakaryopoiesis 
(Kodama T et al. 2012). 
A corollary of these studies is that there is little to suggest megakaryocytes require the 
intrinsic apoptosis pathway to produce platelets. Deletion of BAK1 and BAX does not 
impair thrombopoiesis, in fact platelet counts are significantly elevated due to the extended 
platelet life span that loss of BAK1 confers. Rather than be activated to facilitate 
cytoskeletal rearrangements, the intrinsic pathway must be restrained in order to survive 
and proceed safely through the process of platelet shedding. Treatment of mature wild- 
type mouse megakaryocytes in culture with ABT-737 induces mitochondrial damage and 
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effector caspase activation (Josefsson EC et al. 2011). The result is failure of proplatelet 
formation and death. These effects are mediated by the intrinsic apoptosis pathway, since 
Bak1-/- Bax-/- megakaryocytes are resistant to ABT-737. Other apoptotic stimuli, such as 
the topoisomerase II inhibitor etoposide and the broad-spectrum kinase inhibitor 
staurosporine (STS), also trigger mitochondrial damage and caspase activation. 
Interestingly, however, while deletion of BAK1 and BAX can prevent etoposide- induced 
mitochondrial damage and caspase activation, it does not rescue proplatelet formation, 
suggesting that DNA damage signals suppress platelet shedding independently of the 
apoptotic pathway being engaged. While some differences are observed in vivo, the basic 
premise is the same. ABT-737 does not appear to kill wild-type megakaryocytes in situ, 
but in mice with a megakaryocyte-specific deletion of MCL1, it induces the fulminant 
apoptotic death of megakaryocytes within 3 h (Debrincat MA et al. 2012; Kodama T et al. 
2012). These data suggest there might be subtle differences in MCL1 expression or 
protein-protein interactions in cultured megakaryocytes versus their counterparts in vivo, 
potentially the result of the latter’s exposure to a range of pro-megakaryocytic cytokines 
and growth factors. Regardless, activation of apoptosis is accompanied by a failure of 
platelet shedding and severe thrombocytopenia. As expected, deletion of BAK1 and BAX 
renders MCL1-deficient megakaryocytes entirely refractory to the effects of ABT-737 in 
vivo (Kodama T et al. 2012). 
Finally, data obtained with transgenic mice are in part contradictory in respect to previous 
observations on cultured primary human CD34+-derived megakaryocytes. This may reflect 
differing experimental procedures and types of MKs used in the studies, and so the role of 
Bcl-2 family in megakaryocytopoiesis and platelet production needs to be clarified. 
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1.1.4 PLATELET PRODUCTION FOR INFUSION 
Platelets are essential for haemostasis, accordingly, patients with low numbers of 
circulating platelets or functionally hyporeactive platelets are at increased risk of 
spontaneous bleeding or hemorrhage following traumatic injuries or during surgical 
procedures. Thrombocytopenia (defined as platelet counts <150000/ul) is a major clinical 
problem encountered across a number of conditions, including immune thrombocytopenic 
purpura, myelodysplastic syndromes, chemotherapy, aplastic anaemia, human 
immunodeficiency, virus infection, complications during pregnancy and delivery, and 
surgery. 
The therapeutic strategy to prevent severe bleeding is platelet transfusion. The first 
evidence supporting the use of platelet transfusion was reported in 1910 and since 1950 
was developed the ability to prepare platelet concentrate that are currently used in patients 
with severe thrombocytopenia (Duke WW. 1983; Dillard GH et al. 1951). The use of 
transfused platelets has increased more than other blood components in the last two 
decades (Lu SJ et al. 2011), they derive entirely from human donors however, there are 
several limitations and challenges with platelet preparation and storage technologies. One 
of these limitations is the dependence upon a large donor pool. Because of the limited 
donor supply, there is often a shortage of available blood products. Compounding the 
challenges of availability is the half-life of transfused platelets (3 days), which is 
significantly shorter than the half-life of platelets in vivo (approximately 8-12 days) 
(Dumont L et al. Rossi’s principles of transfusion medicine. 4th ed. AABB/Blackwell; 
2009). Transfused platelet units also have approximately 50% recovery (Filip DJ, Aster 
RH. 1978). Therefore, approximately twice as many platelets need to be given to achieve 
the expected platelet count rise. Finally, platelet reactivity decreases with time of storage: 
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among the mechanisms implicated are platelet activation and apoptosis (Ohto H, Nollet 
KE. 2011; Egidi MG et al. 2010). This poor recovery and decreased platelet half-life and 
reactivity with time is termed the “platelet storage lesion”, and it is reduced by room 
temperature storage (Ohto H, Nollet KE. 2011). On the other hand, because of the need to 
store at room temperature, bacterial contamination of platelets is a significant issue10 with 
the result that platelets have a short shelf life of 5 days. In addition, over 10% of multiply 
transfused patients develop decreased responsiveness to platelet transfusion with time 
(platelet refractoriness). (Bordin JO et al. 1994). 
On these basis, a long-term goal for the field of hematology is to obtain an unlimited 
supply of platelets for transfusion making platelet ex vivo and several strategy are under 
study. 
The ability to grow ex vivo of human megakaryocytes derived from peripheral blood stem 
cells was first described in 1990 when Mazur and colleagues used serum from aplastic 
dogs to stimulate megakaryocyte development (Mazur EM et al. 1990). With the isolation 
and identification of thrombopoietin in 1994 (de Sauvage FJ et al. 1994; Wendling F et al. 
1994) and the subsequent cloning 
 
and generation of recombinant TPO from both humans 
and mice (Sohma Y et al 1994; Lok S et al. 1994; Kuter DJ et al. 1994), it became possible 
to culture sufficient megakaryocytes both for studies of their biology and also to 
contemplate harvesting ex vivo-generated platelets for clinical application. The first report 
of functional human platelets obtained by a two-step culture process was in 1995 (Choi ES 
at al. 1995), showing that megakaryocytes, larger proplatelets, and smaller, platelet-sized 
particles could be generated in vitro from CD34+ peripheral blood cells in the presence of 
appropriate cytokines. These ex vivo-generated platelets have normal platelet morphology, 
surface expression of glycoproteins, and ultrastructural characteristics, including the 
presence of alpha, dense, and lysosomal granules and are responsive to agonist stimulation 
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(Guerriero R et al. 1995; Tao H et al. 1999). However it has been difficult to assess the in 
vivo half-life, functionality, ability to significantly raise platelet counts, and potential to 
reverse a bleeding diathesis, in large part due to the difficulty harvesting these ex vivo- 
generated platelets. One strategy for large-scale production of non- donor-derived platelets 
would be to have a continuous supply of homogenous progenitors that, upon appropriate 
stimulation, differentiate into megakaryocytes. The development of human embryonic 
stem cells (hESCs) (Thomson JA et al.1998) and induced pluripotent stem cells (iPSCs) 
(O’Malley J et al. 2009) provides a renewable source of cells with the potential to expand 
indefinitely in culture and eliminate the need for human donors. Platelet produced from 
hESCs, for the first time in 2006, and from iPSCs, for the first in 2010, show 
morphological features comparable to plasma-derived human platelet, the ability to 
respond to platelet agonists, and to be incorporated into a developing thrombus in vivo 
(Gaur M et al. 2006; Zingariello M et al. 2010; Takayama N et al. 2008; Shattil SJ et al. 
1985; Lu SJ et al. 2011). Despite encouraging first steps in generating clinically useful 
platelets beginning with hESC/iPSCs, two major roadblocks have been identified. The first 
is that the number of megakaryocytes generated per initial progenitor cell is orders of 
magnitude too low, beginning with one progenitor cell <10 megakaryocytes are obtained 
(Reems JA. 2011). The second roadblock is the efficiency of platelets produced per 
megakaryocyte. In order to increase in vitro platelets production yields, recently a 
microfluidic platelet bioreactor has been developed: it recapitulates bone marrow stiffness, 
extracellular matrix composition, micro-channel size, hemodynamic vascular shear stress, 
and endothelial cell contacts, and supports high-resolution live-cell microscopy and 
quantification of platelet production. Physiological shear stresses triggered proplatelet 
initiation, reproduced ex vivo bone marrow proplatelet production, dramatically increasing 
the amount of producing platelets MKs (Thon JN et al. 2014). 
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Nonetheless, due to the clinical and economical interests, further studies on 
megakaryocytopoiesis and platelets production biology need to be performed in order to 
discover optimal conditions of culture and achieve an increased platelets yields.  
Beside bioreactors, other different approaches must be tested, such gene therapy or 
pharmacological approaches that are rationally designed to interact with pathways 
involved in the megakaryocytopoiesis and platelets production.  
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1.2 PLATELETS 
In 1862, Giulio Bizzozero, the so-called ‘father of the platelet’, described a novel 
‘morphological element’ in the blood with important roles in haemorrhage and thrombosis 
(de Gaetano G. 2001). These elements became known as platelets, and they are the 
smallest, circulating, anucleate cells that are derived from megakaryocytes within the bone 
marrow. There are 150–400 × 109 platelets per litre of blood and because the lifespan of an 
individual platelet is only 8–10 days, 100 billion new platelets must be produced daily 
from bone marrow megakaryocytes in order to maintain normal platelet counts 
(Kaushansky K. 2006). 
Their primary physiological role is to sense damaged vessel endothelium and accumulate 
at the site of the vessel injury, where they initiate blood clotting to block the circulatory 
leak. Platelets circulate at high-shear rates and are activated following binding to the 
collagen substratum or to other extra- cellular matrix proteins that are exposed during 
vascular injury. Stable adhesion to collagen promotes the release of many soluble 
mediators from the platelet’s intracellular stores, leading to further platelet recruitment and 
activation. These events are regulated by complex interactions involving several families 
of molecules, including various selectins, integrins, lipids and cytokines. Together with 
leukocytes and red blood cells, the activated platelets create a thrombus that arrests blood 
loss (Gawaz M. 2006). 
1.2.1 PLATELET STRUCTURE 
Platelets circulate in blood with a typical discoid shape, the surface of each disc is 
featureless, lacking protrusions. Plug formation requires platelets to undergo rapid 
morphological changes as they convert from their resting discoid forms to their active 
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shapes. The first event that is observed as the platelet makes contact with the surface, is 
that the discoid shape is lost and becomes rounded or spheroid in form. Next, fingerlike 
projections grow from the cell periphery, then the platelet flattens over surfaces and broad 
lamellae are extended. (Figure 1.2.1). 
 
Figura 1.2.1. Platelet shape change in resting and activated states (White JC. Platelets 3
rd
 edition) 
 
Platelet structure should be divided in: 
• peripheral zone 
• sol-gel zone 
• platelet membrane systems 
Pheripheral zone 
The peripheral zone is formed by an exterior glicocalix and a lipid bilayer. 
The lipid bilayer is a typical unit membrane that does not differ in appearance from the 
membrane covering other cells (White JG, Conrad WJ. 1973), it is incompressible and 
cannot stretch, but it is significantly different because of its role in the acceleration of 
blood coagulation participating to thrombin generation. Clotting is initiated at the site of 
vascular injury by tissue factor (TF), which serves as a cofactor for the coagulant protein, 
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factor VIIa, in converting factor X to Xa. Factor Xa, in association with factor Va, converts 
prothrombin to thrombin on the surface of the anionic phospholipid, phosphatidylserine. 
Platelet lipid bilayer plays a key role in this process because phosphatidylserine is provided 
by surface of activated platelets, and, on the other hand, platelets also contain TF encrypted 
with the cholesterol-rich lipid islands in the resting platelet surface membrane (Heijnen HF 
et al. 1998).  
The platelet glicocalix is thicker then in other blood cells and this exterior surface does not 
serve merely as a barrier to separate internal contents of platelets from the external milieu; 
rather, it is a very dynamic structure that serves as the site of first contact and senses 
changes in the vascular compartment requiring the hemostatic response of platelets at sites 
of vessel injury. The glycocalyx is covered with major and minor glycoprotein receptors 
necessary to facilitate platelet adhesion to a damaged surface, trigger full activation of the 
platelet, promote platelet aggregation and interaction with other cellular elements, and 
accelerate the process of clot retraction (Clemetson KJ et al. 1985; Carrell NA et al. 1985; 
Kunicki TJ. 1988). 
Platelet receptors include integrins, Leucine-Rich repeat family, Seven Trans-membrana 
Receptors and Immunoglobulin superfamily. 
Among integrins, the GpIIbIIIa complex, also named αIIbβ3, is the only integrin expressed 
uniquely on platelets and megakaryocytes. αIIbβ3 represents 3% of the total platelet 
protein and 17% of the platelet membrane protein mass
 
with 50000 to 100000 copies per 
platelet (White JG, Krumwiede M. 1985; White JG et al. 1986; White JG, Sauk JJ. 1984). 
Platelet α-granule membranes also contain αIIbβ3, and this pool can become accessible 
and is functional upon platelet stimulation (White JG, Krivit W. 1967; Whie JG. 1968).
 
Central to the function of integrin αIIbβ3 is its capacity to undergo activation, a transition 
from a low-affinity state (resting state) to a high-affinity state (active state) for its extra-
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cellular ligands during platelet activation and clot formation. When platelets encounter any 
one of a number of agonists, a series of intracellular signaling events are triggered that 
converge at the cytoplasmic tails (CT) of αIIbβ3. Changes in the CT are then transmitted 
across the platelet membrane and transform the extracellular domain of αIIbβ3 into a high-
affinity state for its extracellular ligands. As a consequence, αIIbβ3 can now bind divalent 
fibrinogen or multivalent von Willebrand factor (VWF) (Hynes RO. 1992), which can 
bridge platelets together to form aggregates. Recognition of other ligands, such as 
vitronectin, fibronectin, and thrombospondin (Hynes RO. 1992; Plow EF et al. 2000; Plow 
EF, Shattil SJ. 2001; Reheman A et al. 2005),
 
by αIIbβ3 may mediate platelet adhesion to 
components of the subendothelial matrix and regulate platelet aggregation. 
The α2β1 is an integrin also known on platelets as GPIa-IIa and on lymphocytes as VLA2 
(Staatz WD et al. 1989). There are 2000 to 4000 copies per platelet. α2β1 is well 
established as a major collagen adhesion receptor on platelets and a wide range of other 
cells. 
Other platelet integrins are α5β1 and α6β1, that represent respectively fibronectin and 
laminin receptor, they have a supplementary role in in platelet adhesion at injury sites 
(Piotrowicz RS et al. 1988; Sonnenberg A et al. 1988). 
The leucine-rich repeat (LRR) family is represented in platelets mainly by the GPIb-IX-V 
complex. The GPIb-IX-V is the second most common receptor, in platelet with 
approximately 50000 copies per platelet. Functions of GPIb-IX-V include regulating 
platelet adhesion to subendothelial matrix, endothelial cells or leukocytes, assembly of 
procoagulant activity on activated platelets, and signaling, mediated in part by association 
of GPIb-IX-V with accessory signaling receptors and localization in lipid rafts. GPIb-IX-V 
is the most important receptor for VWF and exposure of vascular subendothelium under 
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high shear results in the immediate attachment of GPIb-IX to von Willebrand factor 
(VWF) covering collagen fibers in the wound (White JG. 1987). 
In platelet, Seven Trans-membrana Receptors include thrombin receptors, ADP receptors, 
tromboxane and prostaglandines receptors. 
Thrombin receptors (PARs) are major representatives of the seven-transmembrane receptor 
group on platelets, because thrombin is a critical platelet agonist. Human platelets have 
about 2,500 copies of the PAR1 receptor, which responds to levels of thrombin of about 1 
nM and a lower number of copies of PAR4 (Andersen H et al. 1999),
 
which is sensitive to 
concentrations of thrombin 10 times higher than PAR1. 
P2Y1 and P2Y12 are platelet ADP receptors.  ADP is one of the earliest identified primary 
platelet agonists. It has also a critical autocrine role, via secretion from dense granules,. 
Recently, ADP receptors have been definitively identified. 
One of the major member of platelet immunoglobulin superfamily, is GPVI. This protein is 
exclusively expressed on platelets and megakaryocytes with 4000-6000 copies per platelet. 
It is a low affinity collagen receptor and it actives a second collagen receptor, integrin 
α2β1. The binding of collagen to integrin α2β1 contributes to stable adhesion and 
reinforces binding to GPVI (Furihata K et al. 2001; Best D et al. 2003; Samaha FF et al. 
2005; Senis YA et al. 2009). The immunoglobulin superfamily also includes: 
• FcγRIIa (CD32), which is a low-affinity receptor for the IgG Fc domain in platelets, 
has a role in heparin-induced thrombocytopenia (Carlsson LE et al. 1998). 
Antibodies are developped against the heparin/platelet α-granule chemokine 
(platelet factor 4) complex, inducing platelet activation via FcγRIIa and, eventually, 
leading to thrombocytopenia. 
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• FcεRI, the high-affinity receptor for IgE,
 
is a platelets activator (Joseph M et al. 
1997; Hasegawa S et al. 1999). 
Integrin-associated protein (CD47) is a receptor for the cell-binding domain of 
thrombospondin (TSP). TSP can mediate platelet activation and aggregation. 
The endothelial cell-selective adhesion molecule (ESAM), that localizes to platelet-platelet 
contacts, regulates thrombus formation in vivo (Stalker TJ et al. 2009). 
Sol-gel zone 
The sol-gel zone consist of a meshwork of fibrous material in which formed organelles are 
imbedded. 
Fibrous material represents platelet cytoskeleton that serves as a system of molecular struts 
and girders that defines the discoid shape of the resting platelet and maintains cell integrity 
as platelets encounter high fluid shear forces generated by blood flow over the 
endothelium. Critical components of this system are, from the plasma membrane inward, a 
spectrin-based skeleton (Boyles J et al.1985; Fox J et al. 1988), a microtubule coil and a 
rigid network of crosslinked actin filaments. (Figures 1.2.2, 1.2.3, 1.2.4). 
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Figure 1.2.2. Microtubule coil isolated from human platelets after simultaneous fixation and detergent 
extraction in suspension. The coil has many loops but appears to consist of one microtubule. Mag X 
13000. (White JC. Platelets 3
rd
 edition) 
 
 
 
Figure 1.2.3. Thin section of a discoid platelet cytoskeleton fixed after detergent extraction in presence 
of lysine and phalloidin. The microtubule is well preserved (T). Remnants of α granules (G) are 
suspended in a matrix of microfilaments (MF) resistant to detergent extraction. Mag X 22000. (White 
JC. Platelets 3
rd
 edition) 
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Figure 1.2.4. Cross-section of a discoid platelet cytoskeleton. The cell is from a sample of C-PRP 
treated with Taxol (1024 M) before extraction. Microtubule (T) profiles are evident at the polar ends of 
the cell. A meshwork of microfilaments (MF) replaces the cytoplasmic matrix. Although the surface 
membrane is gone, a fine amorphous layer remains in its place, probably submembrane filaments. 
Mag.X22,000. (White JC. Platelets 3
rd
 edition) 
 
A spectrin-based skeleton is a two-dimensional assembly of spectrin strands that is 
adherent to the cytoplasmic side of the plasma membrane. It shows both binding sites for 
membrane glicoprotein and for actin, connecting platelet membrane to the actin network 
(Glenney J, et al.  1982; Gratzer W. 1978; Wasenius VM et al. 1989; Winkelmann J et al. 
1990). 
Platelets contain a long microtubule, composed by tubulin molecules, that is approximately 
100 μm in length and 25nm in diameter. To fit the long microtubule inside the resting 
platelet, it is wound from 8 to 12 times into a coil. The coil sits in the cytoplasm, just 
beneath the plasma membrane, along the thin edge of each disc. This microtubule coil is a 
cytoskeletal support system, responsible for distorting the cell into a discoid shape. 
The third components of platelet cytoskeleton is a network of crosslinked actin filaments, 
also named microfilaments. Actin is the most abundant of all the platelet proteins. The 
concentration of actin in a platelet is 0.55 mM, which translates into approximately two 
million copies per platelet (Nachmias VT. 1980).
 
Of these molecules, 800000 assemble to 
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form the 2000 to 5000 linear actin polymers that form the cytoskeleton of the resting cell 
(Hartwig J, DeSisto M. 1991).
 
All evidence indicate that the filaments of the resting 
platelet are interconnected at various points to form a mechanically rigid cytoplasmic 
network. Indeed, platelets express high concentrations of actin cross-linking proteins, 
including filamin (FLNa and FLNb) and α-actinin (Feng Y, Walsh CT. 2004; Stossel T et 
al. 2001). In the resting cell, the microfilament network serves as the matrix on which all 
organelles and other structural components are suspended and maintained separate from 
each other (Escolar G et al. 1986). Following platelet activation, a large amount of actin 
molecules polymerize, and microfilaments have a unique role in contractile physiology. 
They constrict the circumferential microtubule coils and drives the α granules and dense 
bodies into close association in platelet centers. If stimulation is strong enough, granule 
and dense body contents are secreted to the exterior via channels of the OCS (Escolar G et 
al. 1986; White JG, Krumwiede M. 1987), leaving behind a dense, central mass of actin. 
All platelet organelles, such as mitochondria, ribosome and Golgi complex, are imbedded 
in this network of microtules and microfilaments; in particular platelet cytoplasm is rich of 
three major types of secretory organelles, α granules, dense bodies (δ granules) and 
lysosomes. 
α-Granules are unique to platelets and are the most abundant platelet granules. There are 
approximately 5 α-granules per platelet, ranging in size from 200 to 500 nm (Frojmovic 
MM, Milton JG. 1982).
 
They constitute approximately 10% of the platelet volume and the 
total α-granule membrane surface area per platelet is 14 μm. Morphologic features, that 
have historically defined α-granules, include: (1) the peripheral membrane of the granules, 
(2) an electron-dense nucleoid that contains chemokines and proteoglycans, (3) a less 
electron-dense area adjacent to the nucleoid that contains fibrinogen, and (4) a peripheral 
electron-lucent zone that contains VWF (Harrison P, Cramer EM. 1993). α-granules 
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contain both membrane bound proteins, that become expressed on the platelet surface after 
membrane fusion, and soluble proteins, that are released into the extracellular space.  This 
granule content include integral membrane proteins (αIIbβ3, GPIbα-IX-V, GPVI, P-
selectin), coagulant and anticoagulants proteins (Factor V, factor IX, factor XIII, 
plasminogen, plasminogen activator inhibitor), adhesion proteins (Fibrinogen, von 
Willebrand factor, thrombospondin), chemokines, growth factors, angiogenic factors. 
(Berger G et al. 1996; Maynard DM et al. 2007; Nurden P et al.2004). 
Human platelet dense bodies (DB) are smaller than the α-granules (diameter of 150nm), 
are fewer in number (3-8 per platelet), and have high morphological variability (Berger G 
et al. 1996). Their most distinguishing feature is the electron-opaque spherical body within 
the organelle, which is however separated from the enclosing membrane by an empty 
space. This feature led to the term “bull’s-eye” being used to describe the dense body. 
However, some DB are irregular in shape, have filaments extending from the dense inner 
core to the enclosing membrane, or contain a granule-like substance filling the usually 
empty space. Platelet dense granules contain Adenine nucleotides, ADP and ATP,
 
polyphosphates,
 
bioactive amines, such as serotonin and histamine (Holmsen H, Weiss HJ. 
1979; Ruiz FA et al. 2004). Dense granule membrane proteins include those that are 
typically sorting into lysosome-related organelles such as CD63 (granulophysin) and 
LAMP-2. Several platelet plasma membrane have also been identified in dense granule 
membranes, including GPIb and αIIbβ3 (Youssefian T, et al. 1997). 
Platelets contain few primary and secondary lysosomes, approximately 3 lysosmes per 
platelet with a diameter of 200-250nm. Platelet lysosome function is not well studied. It is 
possible that lysosomes may have a role in endosomal digestion, as observed in nucleated 
cells. Indeed, lysosomes contain protein-degrading enzymes (Cathepsins, elastase, 
collagenase, carboxypeptidase, proline carboxypeptidase), carbohydrate-degrading 
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enzymes (Glucosidase, fucosidase, galactosidase, glucuronidase, mannosidase, 
hexosaminidase, arabinofuranosidase), and phosphate ester-cleaving enzyme (acid 
phosphatase). Their membrane expresses CD63 and LAMP-2. 
Membrane system 
The platelet membrane system includes the Open Canalicular System (OCS) and the Dense 
Tubular System (DTS). The OCS is not merely connected to the platelet surface 
membrane; it is a continuum with the surface membrane. (Behnke O. 1967; Behnke O. 
1968; Breton-Gorius J. 1975). OCS channels are tortuous invaginations of surface 
membrane tunneling through the cytoplasm in a serpentine manner. Channels of the OCS 
greatly expand the total surface area of the platelet exposed to circulating plasma and 
provide a means for chemical and particulate substances to reach the deepest recesses of 
the cell (Frojmovic MM et al. 1992; White JG. 1972). As a result, the OCS may be the 
major route to uptake and transfer products, such as fibrinogen, from plasma to platelet α 
granules. (White JG, Escolar G. 1991; Escolar G, White JG. 1991). In addition, channels 
of the OCS serve as conduits for the discharge of products stored in secretory organelles 
during platelet activation. Channels of the OCS also have major roles in the platelets’ 
hemostatic reaction. After adhesion to a damaged vascular surface, platelets extend 
filopodia to bind firmly the injured area, which is followed rapidly by the assembly of 
cytoplasmic actin and the spreading of the platelet to cover as much area as possible. The 
result is an increase of up to 420% of its exposed surface area during conversion from a 
discoid platelet to a fully spread cell. Evaginated channels of the OCS are the major source 
of membrane for the expanded surface area of the spread platelet (Escolar G et al.1989). 
Channels of the DTS are distinguished from clear canaliculi of the OCS by an amorphous 
material similar in opacity to surrounding cytoplasm concentrated within them (Behnke O. 
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1967) that stains for peroxidase (White JG. 1972) and binds ead,
 
indicating calcium 
binding sites and enzymes involved in prostaglandin synthesis  (Gerrard JM et al. 1976). 
Like the OCS, channels of the DTS are randomly dispersed in the platelet cytoplasm. In 
addition, a channel or two of the DTS can be identified in close association with the 
circumferential band of microtubules in most thin sections of platelets. The DTS originates 
from rough endoplasmic reticulum in the parent megakaryocyte and is therefore residual 
smooth endoplasmic reticulum. There is no physical communication between channels of 
the OCS and DTS. The physiological role of DTS is not full understand. 
  
1.2.2 PLATELET TRANSCRIPTOME AND PROTEOME 
Proteins are the chief effectors of cell function. The total complement of proteins present in 
a cell at any given time is known as its proteome, which is under regulatory control and 
varies from cell to cell. The cell proteome is specified by information encoded by nuclear 
DNA, which is transcribed into messenger RNA (mRNA). The total amount of mRNA is 
named transcriptome and cells use template mRNAs to synthesize proteins through a 
process referred to as translation. 
Because platelets lack nuclei, transcription of mRNA is not an option outside of the 
mitochondria, and so the about 3000-6000 transcripts identified in platelets, including 
microRNA are transcribed in megacaryocytes and then packaged into mature platelets. 
However, because of platelets possess a functional spliceosoma, the complex that processs 
pre-mRNA, their transcriptome is not static (Gnatenko, DV, et al. 2003; Lindemann, S and 
Gawaz, M. 2007; Landry P et al. 2009). 
Additionally emerging evidence indicates that megakaryocytes invest platelets with thou- 
sands of proteins, but platelets also contain ribosomes. Therefore, platelets are competent 
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for translation and several studies have revealed that the platelet proteome is complex, 
under regulatory control and subject to change in disease situations and during platelet 
storage (Denis MM et al. 2005; Schwertz H et al. 2006). 
On these basis it is evident that platelet transcriptome and proteome of newly released 
platelet may represent specific features of megakaryocytic precursor, but, on the other 
hand in mature platelet the content of mRNAs and proteins may reflect maturation process 
necessary for platelet functions. 
Collectively analysis of platelet transcriptome and proteome allow the identification of 
feature linked to physiological and pathological conditions.  
 
1.2.3 PLATELET FUNCTION 
The most relevant physiological role of platelets is primary hemostasis, i.e. the timely 
formation of a plug at site of vascular injury in order to prevent hemorrhage.  
As general overview (Figure 1.2.5), prior to vascular injury, intact endothelium provides a 
non-adhesive surface to platelets and platelet activation is suppressed by endothelial cell-
derived inhibitory factors (prostaglandin PGI2, nitric oxide, and CD39, an ADPase on the 
surface of endothelial cells that can hydrolyze trace amounts of ADP that might otherwise 
cause inappropriate platelet activation). After endothelial damage, the development of the 
platelet plug is initiated by thrombin and by the collagen-von Willebrand factor complex, 
which capture and activates moving platelets. Platelets adhere and spread, forming a 
monolayer. Next, the platelet plug is extended as additional platelets are activated via the 
release or secretion of thromboxane A2 (TXA2), as well as ADP and other platelet 
agonists, most of which are ligands for G protein-coupled receptors on the platelet surface. 
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Activated platelets stick to each other via bridges formed by the binding of fibrinogen, 
fibrin, or VWF to activated αIIbβ3. Finally, close contacts between platelets in the growing 
hemostatic plug, along with a fibrin meshwork, help to perpetuate and stabilize the platelet 
plug. 
 
 
Figure 1.2.5. Stages in platelet plug formation. (Brass LS et al. Platelets 3
rd
 edition) 
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In more details, plug formation is usually divided into 4 phases: adhesion, activation, 
aggregation and thrombus stabilization. 
After vascular injury the first interaction between platelet and sub endothelial matrix is 
mediated by VWF and platelet VWF-receptors. Subendothelial VWF binds rapidly platelet 
GPIb-IX-V complex. This interaction has limited lifetime and, although it cannot support 
stable adhesion, it allow the creation of stable adhesion between platelet and endothelium 
through binding of sub endothelial collagen to its receptor GPVI and α2β1.   
This stable adhesion is followed by platelet activation. The interaction of platelet receptors 
with their ligands activate many intracellular signaling that involves primary PI3K/AKT 
pathway which is responsible of a broad range of biochemical and functional platelet 
responses. In particular, during platelet activation there is a microfilaments rearrangement 
followed by platelet shape change, intracellular calcium mobilization, thromboxane 
production, granule secretion with release of platelet agonists and conformational change 
of αIIbβ3 from the ligand low-affinity to the ligand high-affinity state. These mechanisms 
induce the following phase of aggregation, in which thromboxane and other platelet 
agonists interact with their receptors and amplify platelet activation, fibrinogen molecules 
create a bridge with its two extremities for αIIbβ3 integrins on different platelets, and other 
blood cells are recruited stabilizing the platelet plug. (Figure 1.2.6 and Figure 1.2.7) 
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Figure 1.2.6. Platelet receptor and ligand interactions during primary adhesion and subsequent 
platelet activation. Schematic representation of the key ligands and receptors essential for primary 
platelet adhesion(A) and the subsequent signaling events following receptor ligation (B). (Ruggeri ZM 
and Jackson SP. Platelets 3
rd
 edition) 
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Figure 1.2.7. Platelet aggregation and co-stimulation of platelet receptors by soluble agonists. (Ruggeri 
ZM and Jackson SP. Platelets 3
rd
 edition) 
 
1.2.4 PLATELETS AND ATHEROSCLEROSIS  
In the last 15 years is emerged a key role of platelets in the pathogenesis of atherosclerotic 
disease, such as Myocardial Infarction (MI).  
Atherosclerosis is the result of a complex pathological process characterized by vessel 
intimal lesions called atheromata (or atheromatous plaques) that protrude into the vessel 
lumen. Inflammation, focal intimal thickening, and lipid accumulation are key features of 
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this multifactorial process. Endothelial cells, monocytes and platelets are the principal cells 
involved in these events.  
Atherosclerosis has been defined as a reaction to damage in which prolonged injury to 
endothelium in predisposed vessels (e.g. coronary arteries) leaded to events in which 
monocytes and lipids play a central role. If inflammation occurs, endothelial cells become 
a sticky surface to monocytes, allowing them to adhere and, in the setting of high plasma 
cholesterol levels, leads to lipid accumulation within the vascular wall. Lipids are oxidized 
and engorged by monocytes-derived macrophages, due to lipid engulfment, becomeing 
foam cells. Oxidized lipids have a proinflammatory effect, thus perpetuating the 
inflammatory state within the plaque. The vessel wall responds to injury and inflammation 
by inducing the migration of smooth muscle cells from the media to the intima. Moreover, 
smooth muscle cells proliferate and produce extracellular matrix (ECM) components, 
including collagen, elastic fibers, proteoglycans. Thus, the atherosclerotic lesion growths 
and narrows the vessel lumen. The fibrous cap formed by the ECM components prevents 
rupture of the plaque until destabilizing factors occur. Each plaque has a variable 
propensity to rupture. Recent research has shown that inflammation plays a key role in 
plaque rupture: many of the immune cells (macrophages, T cells, and mast cells) at sites of 
plaque rupture exhibit signs of activation and produce several types of molecules 
(inflammatory cytokines, proteases, coagulation factors, radicals, and vasoactive 
molecules) that can destabilize lesions (Kovanen PT et al. 1995; Hansson GK et al. 1989; 
van der Wal AC, et al. 1994), they inhibit the formation of stable fibrous caps and attack 
collagen in the cap (Hansson GK et al. 1989; Amento EP et al. 1991). All these reactions 
can conceivably induce the activation and rupture of plaque. The importance of plaque 
rupture in arterial thrombosis has been undoubtedly recognized (Davies MJ and Thomas 
AC. 1985; Falk E. 1985). The acute complication that develops on the chronic lesions of 
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atherosclerosis after plaque rupture is atherothrombosis. In a physiological setting, self-
limitation of thrombus growth occurs in order to repair damage without disturbing normal 
blood flow. However, when excessive thrombosis occurs, this may impair blood flow 
leading to occlusion of the affected vessel. What it alters the normal balance between pro- 
and antiaggregatory factors is not completely understood, although we know that not all 
lesions are equally thrombogenic. Excessive thrombus formation is plausibly due to 
concurrent combination of high plaque thrombogenicity and platelet hyperreactivity 
(Smitherman TC et al. 1981; Langford EJ et al. 1996; Theroux P and Fuster, V. 1998; 
Vaitkus PT et al. 1995). (Figure 1.2.8) 
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Figure 1.2.8. Pathophysiological events that culminate in thrombus formation (Yeghihazarians Y et al. 
2011). 
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A platelet hyperaggregable state has been documented in many conditions that are well 
identified as risk-factors for cardiovascular events, such as diabetes mellitus, smoking, 
hypertension, hypercholesterolemia, and hyperhomocysteinemia (Willoughby S et al. 
2002). In addition, platelet hyperreactivity, owing to increased TXA
2 
receptors in patients 
with myocardial infarction (Dorn GW et al. 1990), lies the foundation of the clinical use of 
aspirin as a priority antiplatelet drug.  
While it is widely accepted that platelets play a significant role in the final step of 
atherosclerosis, i.e. atherothrombosis, their involvement in the initiation of the 
atherosclerotic process has initially received scant attention. Contrary to previous thoughts, 
platelets take part in all stages of vascular disease by interfering with highly dynamic 
processes. They participate in the initiation of the disease, to its progression and acute 
exacerbation but also provide potential regenerative mechanisms (Langer HF and Gawaz 
M. 2008). Abundant indirect evidences and some in vivo studies on knock-out mice 
support the idea that platelets play a crucial role in atherogenesis even in the earliest phases 
(Davì G and Patrono C. 2007). For example, platelet adhere to the endothelium (Figure 
1.2.9) of carotid arteries in apolipoprotein E (apoE)
-/- 
deficient mice even in the complete 
absence of early vascular alterations, before the recruitment of monocytes (Massberg et al. 
2002). 
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Figure 1.2.9. Platelet-endothelium adhesion. Activated endothelium surface expresses P-selectin. 
Platelet surface receptors GPIbα and P-selectin ligand-1 (PSGL-1) interact with endothelial P-selectin 
and mediate platelet rolling. Subsequent firm adhesion is mediated through β3 integrins (Gawaz, et al. 
2005) 
 
In addition, platelets that adhere to the vessel wall at sites of endothelial cell activation 
contribute to the development of chronic atherosclerotic lesion through release of 
chemokines (Figure 1.2.10) (Boring L et al. 1998; Gleissner CA et al. 2008; Koenen RR et 
al. 2009). 
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Figure 1.2.10. Adherent platelets inflame endothelial cells. Firm platelet adhesion involving αIIbβ3 
induces platelet surface exposure of P-selectin (CD62P) and release of CD40L and IL-1β, which 
stimulate endothelial cells to provide an inflammatory milieu that supports proatherogenic alterations 
of the endothelium (Gawaz, et al. 2005) 
 
A localized reduction of atherosclerosis in von Willebrand factor-deficient mice was 
observed (Methia N et al. 2001). Other studies on adhesion molecules lead to the evidence 
that platelet P-selectin facilitates atherosclerotic lesion development (Burger PC and 
Wagner DD. 2003). Neointimal formation after vascular injury, a typical feature of 
atherosclerotic lesion formation, appears to be strictly dependent on platelet, not 
endothelial, P-selectin (Wang K et al. 2005; Dong ZM et al. 2000), and monocyte 
recruitment requires P-selectin to occur (Figure 1.2.11) (Schober A et al. 2002). 
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Figure 1.2.11. Adherent platelets recruit and inflame monocytes. Adherent and/or activated platelets 
initiate monocyte secretion of chemokines, cytokines, and procoagulatory tissue factor, upregulate and 
activate adhesion receptors and proteases, and induce monocyte differentiation into macrophages. 
Thus, platelet-monocyte interaction provides an atherogenic milieu at the vascular wall that supports 
plaque formation (Gawaz, et al.2005) 
 
These findings were confirmed in vivo in apolipoprotein E–deficient mice, where P-
selectin deficiency protects against atherosclerosis (Collins RG et al. 2000). The finding 
that circulating activated platelets exacerbate atherosclerosis and promote foam cell 
formation further support this idea (Huo Y et al. 2003; Daub K et al. 2007). 
The amount of data available hitherto outline a complex intertwisting between thrombosis 
and inflammation, since many of the molecules released by platelets are indeed 
inflammatory cytokines. As mentioned below, platelet alpha granules contain a huge 
amount of different inflammatory mediators, an equipment that cannot exclusively account 
for platelets hemostatic function. Moreover, they express many immune receptors on their 
surface, including the aforementioned P-selectin, as well as integrins, CD40L, CD40, and 
intercellular adhesion molecule-2 (ICAM-2) (von Hundelshausen P and Weber C. 2007). 
Platelet delivery of inflammatory mediators into the local microenvironment determines 
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alterations in the adhesive properties of endothelial cells. In particular, thrombin has a 
relevant role not only in sustaining activation of resting platelets, but also in activating 
endothelial cells and smooth muscle cells (Croce K and Libby P. 2007). 
All these alterations induce adhesion of monocytes to endothelial cells, migration and 
degeneration into foam cells. Thus, inflammatory, atherogenetic and thrombotic events 
appear to be more and more inseparable processes (Gawaz M et al. 2005; Lindemann S et 
al. 2007; Langer HF et al. 2010). 
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1.3 PKC FAMILY 
Protein kinase C (PKC) is a family of serine/threonine kinases identified 30 years ago. 
PKCs act as major mediators of signal transduction pathways and have been shown to 
regulate sets of biological functions as diverse as cell growth, differentiation, apoptosis, 
adesion, migration, transformation and tumorigenicity (Duquesnes N et al. 2011). 
In mammals 10 members of this family have been identified products of seven highly 
related genes. These members have been grouped into 3 classes according to their primary 
structure and activation modes: classical or conventional PKCs (α, βI, βII and γ; cPKCs), 
novel PKCs (δ, θ, ε and η; nPKCs), and atypical PKCs (ζ and ι ; aPKCs). 
Each isozyme is expressed in a wide variety of cell types and multiple isozymes are 
expressed in a single cell, making it an ubiquitous family of enzymes.  
PKC have been shown to be involved in numerous pathological conditions including 
cancer, cardiac and lung diseases, cerebral ischemic and reperfusion injury and diabetes: 
due to their ubiquity, PKC isozymes have therefore been selected as molecular targets for 
therapeutic agents. (Mochly-Rosen et al. 2012) 
1.3.1 PKC STRUCTURE 
All PKCs have a common general structure with 2 principal modules: a N-terminal 
regulatory domain (20-70 kDa) and a C-terminal catalytic domain (~45 kDa) separated by 
hinge region. Throughout the primary sequence of the enzymes, there is an alternation of 
conserved (C1–C4) and variable (V1–V5) regions (Figure 1.3.1). 
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Figure 1.3.1. Schematic structure of the 3 classes of PKCs (Duquesnes S et al. 2011). 
 
The N-terminal regulatory domain primarily serves two functions. Firstly, it contains one 
or more modules (C1, C2, PB1 or phosphatidylserine-binding domains) that, when 
engaged by lipid second messengers or other interacting proteins, tether the enzyme to 
various locations in the cell such as the plasma membrane. In particular the C1 domain is 
the diacylglycerol/phorbol ester binding site, and the C2 domain contains the recognition 
site for acidic lipids and, in some isozymes, the Ca
2+
 -binding site. Secondly, the regulatory 
domain negatively regulates enzymatic activity; the C1 domain is immediately preceded by 
an autoinhibitory pseudosubstrate sequence that closely resembles a PKC substrate site, 
except that the serine/threonine residue is replaced by an alanine. This pseudosubstrate 
sequence binds to the substrate-binding cavity in the C-terminus and blocks catalytic 
activity. Removal of this pseudosubstrate sequence from the kinase domain occurs when 
lipid second messengers bind to the regulatory domain, resulting in substrate binding and 
phosphorylation. (Freeley M et al. 2010) 
C-terminal catalytic domain interacts with substrates and is responsible for 
phosphotransfer activity: it contains the ATP-binding site (C3 domain), the substrate-
binding site (C4 domain) and three key phosphorylation sites that were important for PKC 
function. These phosphorylation sites are known as the activation-loop, the turn motif and 
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the hydrophobic motif and while all three sites are conserved in cPKCs and nPKCs, the 
aPKC do not contain a hydrophobic motif. For the vast majority of PKC isoforms, 
phosphorylation of the activation loop is crucial for catalysis, since mutation of this residue 
to a non-phosphorylatable residue abolishes activity, and this phosphorylation is catalyzed 
by PDK-1 (Phosphoinositide-Dependent Protein Kinase-1). Phosphorylations at turn-motif 
and hydrophobic motif play a role in stabilization of the enzyme rather than directly 
controlling catalytic activity, and, in different PKC isoforms, they are autophosphorylation 
sites or targets for mTOR pathway (mammalian Target of Rapamycin) and chaperon 
proteins that include Hsp family (Heat shock protein) (Freeley M et al. 2010). 
The hinge region is a non-conserved domain, also known as the V3 region. When PKC is 
active, the hinge domain may became labile to proteolytic enzymes such as caspases and 
Ca2+-dependent calpains. Calpains or caspases-mediated cleavage of PKC at the hinge 
domain produces an isolated kinases domain fragment that generally is considered to be 
constitutively active in the absence of any lipid second messengers, provided that these 
domains are phosphorylated at the activation loop (Reyland M.E. et al. 2009; Smith L et al. 
2002). 
PKC activation 
The function of protein kinase C is regulated by two equally important mechanisms. First, 
the enzyme is rendered catalytically competent by phosphorylations that correctly align 
residues for catalysis and localize protein kinase C to the cytosol. Second, binding of 
ligands or, in some cases, substrate activates the enzyme by removing the pseudosubstrate 
from the substrate-binding site (Figure 1.3.2). 
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Figure 1.3.2.Model for regulation of PKC by 1) phosphorylation and 2) membrane binding and 
pseudosubstrate release (Newton AC. 1995) 
 
PKC is first synthesized as an inactive, dephosphorylated precursor, and phosphorylation 
at the activation-loop, turn-motif and hydrophobic motif sites has been described as 
maturational or priming events that are required for the processing of these enzymes to 
signalling-competent (but still inactive) forms. The first event is the transphosphorylation 
at the activation loop to render the kinase catalytically competent, this step is followed by 
autophosphorylation or mTOR pathway-dependent phosphorylation at the turn motif and 
hydrophobic motif that stabilize the catalytically competent conformation and that releases 
protein kinase C into the cytosol (Keranen LM et al. 1995). The enzyme is now in an 
inactive state because the pseudosubstrate occupies the substrate-binding site, but this 
mature form is signalling-competent, it is ready to be activated by lipid second messengers 
such as DAG. 
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The complete activation of PKCs occurs when DAG or phorbol ester bind C1 domain, and 
Ca
2+
 binds C2 domain for cPKCs. These interactions increase PKC’s membrane affinity, 
that is accompanied by pseudosubstrate release and PKC translocation from the cytosol to 
the plasma membranes as well as to other subcellular locations, where each isozyme 
interacts with its anchoring protein, RACK. When bound to RACK and the second 
messenger activators DG (and Ca
2+ 
for the conventional PKC isozymes) (Figure 1.3.3), 
PKC is then active, phosphorylating a number of substrates that are nearby, thus leading to 
diverse cellular responses (Newton AC et al. 1995). 
 
Figure 1.3.3. Interaction of PKCs with RACK (Mochly-Rosen D et al 2011) 
 
A variety of hormons (adrenaline, angiotensin, etc.), groth factors (insulin, EGF, etc.) and 
neuro transmitters (dopamine, endorphin, etc.) when bound to their specific receptors, 
activate members of the Phospholipase C (PLC) family that hydrolizes the phospholipid 
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phosphatidylinositol 4,5-bisphosphate (PIP2) into DAG and inositol 1,4,5-trisphosphate 
(IP3); in turn IP3 induces Ca
2+ 
release from R lumen and increasing of Ca
2+
 concentration 
in the cytosol. Because of DAG production and Ca
2+ 
release these molecules are 
considered PKC activators. 
PKC signalling is terminated by the metabolism of DAG, which results in the translocation 
of cPKCs/nPKCs back to the cytoplasm. It has also been reported that dephosphorylation 
of PKCs can occur at sites such as the A-loop and HM in response to stimuli such as 
Tumor Necrosis Factor-α, which is likely to be a key step in turning off the signalling 
capacity of these kinases (Lee JY et al. 2000). Prolonged PKC signaling, that is promoted 
by phorbol esters or sustained by DAG signaling, results in the downregulation of PKCs 
via the ubiquitin/proteasome system (Lee HW et al. 1996; Lu Z et al. 1998) and studies 
have shown that dephosphorylation of PKCs at the A-loop, TM and HM sites occurs prior 
to down regulation (Hansra G et al. 1999). 
PKC regulation 
Modulation of PKC activity presents an attractive target for clinical drug development for 
several reasons. 1) Isozyme-specific perturbations in PKC activity have been identified in a 
number of human disease states including congestive heart failure (Bowling N et al.1999), 
bipolar disorder (Friedman E et al. 1993; Hahn CG et al 1999) and diabetes mellitus 
(Geraldes P, King GL. 2010; Nishikawa T et al. 2000). PKC isozymes play an important 
role in critical biological processes such as cell proliferation and formation of vasculature 
that are important in tumor growth and metastasis (Podar K et al. 2007; Bosco R et al. 
2011). Animal studies demonstrate a role for individual isozymes in a particular disease 
and/or evidence of therapeutic effects when the isozymes are inhibited or activated 
(DiazGranados N, Zarate CA Jr. 2008; Teicher BA. 2006; Budas GR et al. 2007). A 
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number of pharmacologic agents that are efficacious in disease states have been shown to 
modulate activity of PKC, either directly or indirectly through a signaling cascade (Pravdic 
D et al. 2009; Manji HK, Lenox RH. 2000). 
Different approaches have been developed to identify selective modulator of PKC. These 
include development of (a) ATP-competitive small molecule inhibitors that bind to the 
ATP site of the kinase catalytic domain, (b) phorbol esters and derivative activators and 
inhibitors that bind to the C1 domain, mimicking DG-binding, and (c) inhibitor peptides 
that disrupt protein/protein interactions between the regulatory region and RACK blocking 
PKC translocation to the plasma membrane, or activator peptides that correspond to a 
sequence in PKC that is homologous to its RACK (Figure 1.3.4) (Mochly-Rosen et al. 
2012). 
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Figure 1.3.4. Inhibitors of PKCs (Mochly-Rosen D et al. 2011) 
 
 
Despite most PKCs are ubiquitously expressed, it is clear that specific PKC isozymes 
have unique and sometimes opposing roles in the same cells or in normal signaling and 
disease state.  
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In this context, the most intriguing example is represented by two novel PKC, PKCδ and 
PKCε that mediate contrasting and even opposing effects. In general, PKCε appears thus 
as the “bad” due to its oncogenic properties. It has even been proposed as a tumor marker 
(Gorin MA, Pan Q. 2009). In contrast, PKCδ appears as the “good” with proapoptotic 
properties in cancers and it is an anti-oncogene. Surprisingly, for cardiologists, at least in 
the domain of ischemia, PKCε is the “good” since it has been shown to be a major actor in 
the mechanisms inducing preconditioning. In contrast, inhibition of PKCδ during 
reperfusion protects the heart from reperfusion-induced damage, although both were 
shown to have parallel effects in non-pathological cardiac hypertrophy (Chen L et al. 
2001). Moreover their expression is opposite in human and mouse platelet (Pears CJ et al. 
2008). 
 
1.3.2 PKC EPSILON 
PKCε is a novel PKC that shares many structural features with other members of the PKC 
family including a C1 domain containing two cysteine-rich motifs that bind DAG, a C2-
like phospholipid binding domain, a pseudosubstrate domain, C3 and C4 catalytic domains 
that contain a purine binding site for ATP, and a substrate recognition site.  
 
 
Figure 1.3.5. Schematized primary structure of PKCε (Newton AC et al 2011) 
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A unique feature of PKCε is a 6 amino acid actin-binding motif between the C1a and C1b 
subdomains (Prekeris R et al. 1996). Like other PKC isozymes, PKCε must be primed 
through phosphorylations to display full enzymatic activity and respond to allosteric 
regulators: the phosphorylated sites are the activation loop (Thr
566
), the Thr-Pro turn motif 
(Thr
710
), and the hydrophobic Phe-Ser-Tyr motif (Ser
729
). PDK1 phosphorylates the 
activation loop, whereas the turn and hydrophobic motifs are autophosphorylated in 
cPKCs, and possibly in PKCε: these phosphorylations are regulated (Cenni V et al.2002). 
Following the maturation and the allosterical activation, due to RACK proteins, PKCε 
translocates to specific subcellular compartments. RACK2 is PKCε-specific, but this 
isoform can interact also with RACK1 to regulate integrin-mediated cell adhesion and 
motility (Csukai M et al. 1997; Xu TR et al. 2007).  
PKCε can also bind 14-3-3 proteins in V3 hinge region; during the late stages of mitosis, 
the formation of 14-3-3/PKCε complex is required for the separation of two daughter cells 
(cytokinesis) during abscission, the final stage of the cell cycle. Mutation of V3 
phosphorylation site prevents this association and impairs completion of cytokinesis; 
likewise, knockout, depletion or inhibition of PKCε impairs abscission (Saurin AT et al. 
2008). 
PKCε is unique among PKC isozymes in containing an actin-binding region: this six amino 
acid sequence (LKKQET) is located at amino acids 223-228 on PKCε. When PKCε is in 
the inactive state, this region is not exposed and thus actin is not bound; however, 
following treatment with PKC activators such as phorbol esters or DAG, PKCε undergoes 
a conformational change and the actin-binding region is exposed. Interestingly, binding of 
PKCε to actin stabilizes the active conformation of the enzyme. The PKCε-actin 
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interaction has profound consequences for the actin cytoskeleton, most notably promoting 
the formation of actin through several mechanisms, including inhibiting the 
depolymerization of actin and increasing the rate of actin filament elongation (Klauck TM, 
et al. 1996; Prekeris R, et al. 1996; Prekeris R, et al. 1998; Nakhost A, et al. 1998). 
 
Tumorigenic function of PKCε, is the best known and most studied, and PKCε is the only 
isoenzyme that has been considered as an oncogene. The overexpression of PKCε has been 
observed in a large number of cancer types like bladder, brain, breast, head lung and 
prostate (Gorin MA, 2009) and in various cellular models it confers a proliferative 
advantage and increases anchorage-independent growth promoting an invasive metastatic 
tumour-cell phenotype (Cacace, AM. et al. 1996; Mischak, H. et al. 1993; Griner EM. 
2007), these conditions are streakly related to chemotherapeutic resistance in various cell 
types overexpressing PKCε. Moreover transgenic mice overexpressing Pkcε develop 
squamous cell carcinoma with significant metastatic potential and show increased 
sensitivity to UV-radiation-induced carcinogenesis (Wheeler DL et al. 2003; Reddig PJ et 
al. 2000). 
Its oncogenic function is related to the interaction with many signaling pathways. In 
particular it protects cells from apoptosis through the induction of pro-survival proteins 
Bcl2, Bcl-xL, XIAP  (X-linked inhibitor of apoptosis), it controls PI3K-Akt activation and 
it induces activation of mitogen-activated protein kinase (MAPKK or MEK)–ERK 
pathway (Gubina E et al. 1998; Pardo OE et al. 2006). PKCε overexpression prevents 
apoptosis induced by the tumour-necrosis factor (TNF)-related apoptosis-inducing ligand 
(TRAIL); similarly, melanoma cells with low PKCε expression are highly sensitive to 
TRAIL-induced apoptosis (Gillespies S et al. 2005). Moreover, in non-small-cell lung 
carcinoma cells, PKCε blocks mitochondrial-dependent caspase activation and inhibits 
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cytochrome c release (Ding L et al. 2002)
 
while depletion of PKCε in a head and neck 
squamous carcinoma cell line leads to a decrease in motility and invasion through a 
corresponding decrease in RhoA and RhoC activity (Pan Q et al 2006).  
 
Interesting is also the role of PKCε in cardiovascular system and it has been 
demonstrated a cardioprotective function. In facts PKCε activation is protective when 
occurring prior to the ischemic event or right at reperfusion, mimicking protection induced 
by short ischemic period prior to the prolonged ischemic event (pre-conditioning) or right 
at reperfusion (post-conditioning). PKCε activation protects mitochcondrial functions, in 
part via activation of mitochondrial aldehyde dehydrogenase 2 (ALDH2), which removes 
toxic aldehydes, products of lipid per oxidation (Inagaki K et al. 2006; Chen CH, et al. 
2008; Budas GR et al. 2007; Duquesnes N et al. 2011; Yang X et al. 2010). ALDH2 
activation via PKCε and infarct size reduction induced by PKCε activator in Myocardial 
Infarction model, are also associated to inhibition of fatal ventricular arrhythmia (Ferreira 
JC et al. 2012). Moreover Galli et al have demonstrated a critical role of PKCε in 
cardiomyocyte differentiation regulating early and late cardiac genes expression (Galli D 
et al. 2013). 
PKCε is involved in the differentiation of other cell types over that of 
cardiomyocytes.  
In particular, it is involved in the differentiation of intestinal cells, such as in colon 
epithelium, in which it has been described a decreasing gradient of PKCε expression from 
the bottom of the crypts, where intestinal stem cells are resident, to the luminal surface. 
This expression of PKCε at the base of the crypts, mantains the undifferentiated phenotype 
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of intestinal stem cell pool, while the downregulation of PKCε promotes differentiation 
(Perletti GP et al. 1996; Gobbi G et al. 2012).  
Moreover it has been demonstrated a differential levels of PKCε expression during both 
erythropoiesis and megacaryocytopoiesis (Gobbi et al. 2013), suggesting that this 
isoenzyme might be a key factor in orchestrating the MEP differentiation decision along 
the erythroid and megacaryocitic differentiation (Figure 1.3.6). 
 
Figure 1.3.6. Histogram comparing the in vitro timing of protein kinase Cε expression levels along 
thrombopoietin-induced megakaryocytic differentiation (TPO) and erythropoietin-induced erythroid 
differentiation (EPO) (Gobbi G et al 2013) 
  
EPO induce proliferation of early erythroid progenitor poll, decreasing the level of cell 
cycle inhibitors and increasing transcription of cyclins, while late erythroid progenitors 
require EPO as a survival factor that allow them to reach terminal differentiation, 
promoting the expression of antiapoptotic protein of Bcl-2 family. TRAIL is a negative 
regulator of adult erythropoiesis, reducing the number of erythroblasts. During in vitro 
erythropoiesis of human CD34
+
 cells, EPO induces PKCε expression, this isoenzyme 
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progressively reduces the sensitivity of human erythroid progenitors to TRAIL-induced 
apoptosis  via Bcl-2 up regulation, and erythroblast can successfully complete their 
maturation process (Mirandola et al. 2006). Also, both erythroleukemic cell line TF-1 and 
primary acute myeloid leukemia cells, when treated with phorbol 12,13-dibutyrate (PDBu), 
become sensitive to the apoptotic effects of TRAIL via PKCε down-regulation, similar to 
what is observed in early erythropoiesis (Gobbi G et al. 2009). 
 
1.3.3 PKC DELTA 
PKCδ is the first nPKC isozyme to be identified. Its C-terminal catalytic region contains 
C3 and C4 domains, in common with other members of the PKC family. The C4 domain 
contains the activation loop (Thr
505
), turn motif (Ser
643
) and hydrophobic motif sites 
(Ser
662
); the isozyme  maturation through the phosphorylation of these three sites is 
regulated. Differently from other PKCs, PKCδ is a functional kinase even without Thr505 
phosphorylation; this has been attributed to an acidic Glu
500
 in PKCδ that assumes the role 
of the phosphorylated activation-loop Thr in cPKCs. Nevertheless, the catalytic activity of 
membrane-associated allosterically activated PKCδ is increased by Thr505 phosphorylation 
(Gschwendt M. 1999). 
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Figure 1.3.7. Schematized primary PKCδ structure (Atlas of Genetics and Cytogenetics in Oncology and 
Haematology) 
 
As nPKCs, PKCδ has twin C1 domains, a C2 domain and a pseudosubstrate site in his N-
terminal regulatory region. The calcium-binding-like loop of the C2 domain of PKCδ 
contains a sequence that conforms to an optimal Scr family kinases (SFK) substrate; this 
sequence is unique to PKCδ and is not found in other PKC isoforms that do not become 
tyrosine phosphorylated in response to DAG or phorbol esters. No uniform pattern or 
consequence of PKCδ tyrosine phosphorylation can be extracted from the published 
literature, since the catalytic activity of tyrosine-phosphorylated PKCδ is variably 
described as decreased, increased, or even altered with regard to substrate specificity and 
cofactor requirements (Denning MF et al. 1996; Acs P et al. 2000). After the maturation 
through phosphorylation and the allosteric activation by DAG/phorbol esters, PKCδ can 
interact with its isozyme specific RACK protein p32/gC1qBP and translocate to the 
membranes where it performs its catalytic activity (Robles-Flores M et al. 2002). 
The PKCδ hinge domain has been recognized as a caspase-dependent cleavage site, it 
allows the release of a catalytic domain fragment that is freed from autoinhibitory 
regulatory domain, leading to the activation of these PKC and thereby contributing to the 
proapoptotic potential of this isoenzyme (Denning MF et al 1998). 
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PKCδ is primarily know for its tumor-soppresor rule. This isoforme has been show 
to be down regulated in various type of cancers and its depletion confers a malignant 
phenotype (Perletti GP et al. 1999). Phorbol-ester-induced tumour promotion involve the 
downregulation of PKCδ while bryostatin 1, which protects PKCδ from downregulation, 
blocks phorbol-ester-induced tumour promotion, moreover, transgenic mice 
overexpressing PKCδ are resistant to phorbol-ester-induced tumour promotion (Lu Z et al. 
1997; Hennings, H. et al. 1987). This tumor-soppresor rule is closely related to pro-
apoptotic and anti-proliferative PKCδ functions. 
Activation of PKCδ causes proliferation defects both in G1 and G2 phases of the cell cycle 
through the modulation of cyclin expression or the activity of cyclin- dependent kinases, 
with a great degree of cell-type variability (Black JD. 2000; Gavrielides MV et al. 2004). 
PKCδ can downregulate the expression of cyclins A, D1 and E, but can also upregulate 
p27 and p21 expression and PKCδ activation inversely correlates with RB phosphorylation 
(Nakagawa M et al. 2005). However it is important to mention that, in some cell types, 
PKCδ can also positively regulate proliferation, for example, PKCδ is required for the 
proliferative effect of insulin-like growth factor and can induce post-transcriptional 
destabilization of p21 (Walker JL et al. 2006). 
During apoptosis, PKCδ can be activated by proteolysis (Emoto Y et al. 1995), it is highly 
susceptible to caspase-3 cleavage at the hinge region, which results in the generation of a 
~40-kDa C-terminal fragment that is constitutively active. Several chemotherapeutic 
agents, such as etoposide or cisplatin and UV radiation, induce the generation of the 
catalytic PKCδ fragment and, remarkably, their apoptotic efficacy is severely impaired 
when PKCδ function or expression is inhibited (Denning MF et al. 1998; Reyland ME et 
al. 1999; Persaud SD et al. 2005). Most notably, cells from Pkcδ-null mice are defective in 
mitochondrial- dependent apoptosis and caspase-3 activation induced by etoposide 
  Introduction 
 74 
(Humphries MJ et al. 2006). Most evidence point to a dual involvement of PKCδ in the 
apoptotic cascade, both upstream and downstream of caspase-3, with PKCδ cleavage 
serving as a positive feedback signal to amplify caspase-3 activation. Many apoptotic 
stimuli can redistribute PKCδ to the mitochondria, leading to cytochrome c release, 
caspase-3 activation and initiation of the intrinsic apoptotic cycle (Majumder PK et al. 
2000; Denning MF et al. 2002). PKCδ pro-apoptotic function is also associated to 
activation of pro-apoptotic proteins Bax and Bad and inhibition on anti-apoptotic protein 
Bcl2. PKCδ was found to induce the expression of, and associate with, topoisomerase IIα 
in response to genotoxic stress (Yoshida K et al. 2008). This interaction is required for the 
stabilization and activation of topoisomerase IIα and is confined to the S phase of the cell 
cycle and aberrant activation of topoisomerase IIα can trigger the intrinsic apoptotic 
pathway. In prostate cancer cells has determined that PKCδ can trigger an autocrine 
apoptotic loop through the secretion of TNFα and TRAIL (Gonzalez-Guerrico AM & 
Kazanietz MG. 2005). In these cells, the apoptotic effect of phorbol esters is entirely 
dependent on PKCδ and is greatly impaired upon inhibition or RNAi depletion of TNFα 
and TRAIL death receptors and by caspase-8 knock-down. 
Moreover, PKCδ also regulates other biological effectors that are critical for cancer 
biology; for example, PKCδ inhibits basal transcription of the tumor suppressor protein 
p53 in human myeloid leukemia cells. Since p53 is a key element in the surveillance 
mechanism used by cells to maintain genomic stability by eliminating cells with damaged 
DNA, inhibition of p53 is permissive for tumor formation (Abbas T et al. 2004). PKCδ 
activation has also been linked to anchorage-independent tumor cell growth and enhanced 
tumor cell survival. These mechanisms would influence tumor invasion and metastasis, in 
breast cancer cells and mouse embryonic fibroblasts isolated from Pkcd-null mice, 
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downregulation of PKCδ increased cell motility via MMP9 up-regulation (Jackson D et al. 
2005). 
 
Along with PKCε but with an opposite effect, PKCδ is involved in ischemic 
preconditioning and ventricular hypertrophy. Pharmacological PKCδ activation is reported 
to worsen cell damage during an ischemic insult, whereas PKCδ inhibition confers 
cardioprotection. Moreover, in cardiomyocytes, PKCδ has been implicated in the down-
regulation of SERCA2 expression, a characteristic feature of the hypertrophic phenotype; 
and PKCδ over-expression is also reported to activate JNK and p38 MAPK, promote cell 
detachment, and induce cardiomyocyte apoptosis (Steinberg SF, 2004). 
 
In haematopoietic system it has been demonstrated an involvement of PKCδ in erytroid 
and granulocyte differentiation. During erythroid differentiation PKCδ is largely expressed 
during the early phase of proliferation, while must be down regulated to allow terminal 
differentiation (Marchisio M et al. 2005; Lanuti P et al. 2006). Moreover U-937 cells are 
induced to undergo granulocytic differentiation via PKCδ phosphorylation (Zhang HW et 
al. 2008). 
Recently Sassano and co-workers have demonstrated that the pro-differentiative and 
antileukemic effects of statin in acute promyelocytic leukemia cells are mediated by PKCδ 
activation (Sassano et al. 2012). Similarly antileukemic effect of INF-alpha and ingenue 3-
angelate (PEP005) in chronic myelogenous leukemia cells and in primary acute myeloid 
leukemia (AML) cells respectively, are PKCδ dependent (Kaur S et al. 2005; Hampson P 
et al. 2005). 
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1.3.4 PKCε AND PKCδ IN MEGAKARYOCYTOPOIESIS  
The role of PKCε in megakaryocytopoiesis is well described in normal and pathological 
conditions.  
Early observations demonstrated that phorbol ester induces polyploidization and platelet-
specific markers expression in DAMI human MK cell line, and moreover it induces PKC ε, 
α, θ translocation from the cytosol to the cell membrane (Ballen KK, Exp Hematol 1996). 
PKCε participates in MK linage commitment cooperating with GATA-1 in the activation 
of megakaryocytic promoters and its down-modulation inhibits megakaryocytic 
differentiation of K562 cells (Goldfarb J et al. 2001). 
Gobbi et al, have demonstrated that during in vitro megakaryocytic differentiation of 
human CD34
+
 cells, PKCε levels are finely tuned. Progressively increase in the early 
phases of differentiation while decrease in the late phases. An induced persistence of 
elevated PKCε levels interfere with the late phase of megakaryocytic differentiation 
reducing polyploidization, MK-specific markers expression and platelet production.  This 
function of PKCε is related to modulation of Bcl-xL level. It is, in fact, well-know that 
Bcl-xL levels must be down-modulated in the later phases of thrombopoiesis (Sanz C et al. 
2001), but PKCε overexpression results in an accumulation of Bcl-xL that interfere with 
the physiological process of thrombopoiesis (Gobbi G et al. 2007). 
More recently, we have demonstrated a role of PKCε regulation in Primary Myelofibrosis 
(PMF). In this Philadelphia chromosome-negative Myeloproliferative Neoplasm, bone 
marrow MKs are hyperplastic and show typical morphological abnormalities such as 
hypolobated nuclei, tendency to form tight clusters and impaired capacity to generate pro-
PLTs in-vitro. Interestingly PMF-CD34
+
-derived megakaryocytic express higher levels of 
PKCε than those from healthy subjects, these levels also correlate with disease burden. 
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Inhibition of PKCε function restores a normal in-vitro megakaryocytoiesis from PMF 
hematopoietic progenitors (Masselli et al. In Press). 
We have also demonstrated that PKCε is differentially regulated in human and mouse 
megakaryocytopoiesis. Using an in vitro model of murine platelet production, we found 
that PKCε expression escalates during megakaryocytic differentiation but, contrary to the 
human model, it remains elevated in late phase of differentiation and in proplatelets and 
that down-regulation of its expression resulted in decreased proplatelet numbers and larger 
platelets. We propose that the mechanism by which PKCε modulates proplatelet formation 
is through RhoA; inhibition of RhoA reversed the proplatelet defects seen with PKCε 
inhibition (Gobbi et al. 2013).  
 
With regard to the role of PKCδ in megakaryocytopoiesis, it has been only observed that 
K562 and HEL cells show increased levels of PKCδ expression when cultured in presence 
of PMA to induce megakaryocytic differentiation (Zauli T et al. 1996; Fang T et al. 2010). 
 
1.3.5 PKCε AND PKCδ IN PLATELET FUNCTION 
PKC activity has been associated with a variety of platelet functions (Massberg S et al. 
2002). 
PKC activity, in synergy with Ca
2+
, regulates the secretion of dense and α-granules 
following platelet stimulation with phospholipase C-stimulating agonists, like collagen and 
thrombin (Rinck TJ, Deutsch C. 1983; Walker TR, Watson SP. 1993;  Yoshioka A et al. 
2001). Secretion of ADP, fibrinogen, and other stored compounds, in turn, enhance the 
activation process (Jin J, Kunapuli SP. 1998; Paul BZ et al. 1999).  
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PKC-mediated protein phosphorylation also induces the conformational changes of 
integrin αIIbβIII required for fibrinogen binding and platelet aggregation (van Willigen G, 
Akkerman JW. 1991; Hers I et al. 2000). Activated integrins, in turn, stimulate PKC via 
outside-in signaling, resulting in filopodial formation and platelet spreading (Hartwig JH 
et al. 1996; Buensuceso CS et al. 2005). Ca
2+
-dependent PKC isoforms contribute to 
platelet aggregation, directly via integrin phosphorylation and indirectly via granule 
secretion. It has been reported that PKC is involved in Ca
2+
 flux in platelets (Rinck TJ et al. 
1983; Rosado JA, Sage SO. 2000), while under flow conditions PKC contributes to the 
stable adhesion of platelets to collagen but not to their initial attachment to the vessel wall 
(Polanowska-Grabowska R, Gear AR. 1999). Finally, it has been demonstrated that platelet 
PKCs have a dual controlling role in thrombus formation, balancing the proaggregatory 
and procoagulant properties of thrombi (Strehl A et al. 2007) suggesting that the different 
PKC isoforms present in platelets participate to distinct activatory or suppressive 
pathways, the latter of which are mediated by one or more non-classical PKC isoforms 
(Strehl A et al. 2007).  
Notwithstanding these research efforts, a clear picture of the role of the different PKC 
isoforms in platelets is still lacking.  
In particular, focusing on the two novel PKCε and PKCδ, it has been demonstrated that 
delta isoform is expressed in human platelet, and several studies have shown the role of 
PKCδ in many platelet function, such as granule secretion, thromboxane A2 synthesis and 
platelet aggregation. 
In human platelets, collagen or thrombin induce PKCδ Tyr311 and Tyr565 
phosphorylation by Src-family kinases (Murugappan S et al. 2005; Hall KJ et al. 2007), 
which increases PKCδ activity but does not affect plasma membrane translocation (Hall 
KJ et al. 2007). Interestingly, PKCδ tyrosine phosphorylation appears to be regulated 
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differently in mouse platelets, with little phosphorylation being detected after stimulation 
with collagen-related peptide (Pears CJ et al. 2008). That PKCδ regulates granule 
secretion was first proposed on the basis of the reported effects of rottlerin (a PKCδ 
inhibitor). Rottlerin enhances GPVI-dependent granule secretion, but inhibits granule 
release following activation of protease-activated receptor (PAR) 1 or PAR4, suggesting 
that PKCδ regulates dense granule secretion in an agonist-dependent manner (Murugappan 
S et al. 2004). Studies with PKCδ-/- platelets have not fully resolved the role of PKCδ. Pula 
and co-workers, found no difference in GPVI- dependent dense granule secretion in PKCδ-
/-
 platelets as compared with the wild type. Significantly, rottlerin still enhanced granule 
secretion in PKCδ-/- platelets, under- scoring its likely off-target effects, and demonstrating 
that, under these conditions, it was possible to observe a potentiation of secretion (Pula G 
et al. 2006). In contrast, Chari et al. (Chari R et al. 2009) found enhanced GPVI-dependent 
dense granule secretion in PKCδ-/- platelets, an effect replicated in human platelets by a 
specific PKCδ inhibitor peptide. The reasons for this apparent difference are not clear.  
In the same paper Chari et al. (Chari R et al. 2009) also found that PKCδ-/- platelets 
showed partially reduced granule secretion in response to stimulation of PAR4, and dense 
granule secretion was also inhibited by specific PKCδ inhibitor peptide. They indicate that 
reduced secretion was only seen at submaximal concentrations of AYPGKF, and lost at 
higher concentrations, suggesting that other mechanisms may compensate for the loss of 
PKCδ signaling at higher agonist concentrations. The mechanisms that might underlie 
differential regulation of granule secretion by PKCδ by GPVI and G-protein-coupled 
receptor stimulation are still unclear. It has been shown recently that phosphorylation of 
PKCδ by the tyrosine kinase Lyn occurs downstream of GPVI but not PARs, and that Lyn 
and PKCδ together regulate SHIP1 phosphorylation in an agonist-dependent manner 
(Chari R et al. Blood 2009). This is consistent with negative regulation of αIIbβIII
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signaling by a Lyn–SHIP1 complex that has been previously proposed (Maxwell MJ et al. 
2004), and this may begin to explain the differential roles for PKCδ in signaling 
downstream of collagen and thrombin. 
During the activation process, platelets rapidly and transiently extend filopodia, which are 
quickly superseded by lamellipodia to form the fully spread platelet. In PKCδ-deficient 
platelets, however, although both filopodia and lamellipodia do form sequentially, as in 
wild-type platelets, the filopodia do not subsequently disappear, unlike in the wild type, 
where filopodia are not apparent in the fully spread platelet. This sustained appearance of 
filopodia in PKCδ-/- platelets also results in more extensive platelet aggregation. The 
molecular mechanism underlying this functional change involves a physical interaction 
between PKCδ and the actin regulator vasodilator-stimulated phos- phoprotein (VASP). 
PKCδ was shown to negatively regulate phosphorylation of VASP at Ser157, reducing 
filopodial extension or promoting filopodial retraction, and thereby negatively controlling 
platelet–platelet interaction to limit aggregation. 
In contrast, although PKCδ-/- platelets show enhanced collagen/collagen-related peptide-
induced aggregation (Pula G et al. 2006) and, under some conditions, may show slightly 
enhanced GPVI- dependent dense granule secretion, the two are possibly unrelated. 
Inhibition of P2Y1 and P2Y12did not prevent enhanced aggregation in PKCδ
-/-
 platelets 
(Pula G et al. 2006). Furthermore, aggregation of PKCδ-/- platelets could not be further 
enhanced by rottlerin, whereas dense granule secretion was further potentiated. Instead, we 
have proposed that the enhanced aggregation results from increased filopodia formation in 
PKCδ-/- platelets (Pula G et al. 2006). 
Regarding to the PKCε, its expression is still a matter of debate. Most Authors do not find 
it (Buensuceso CS et al. 2005; Pears CJ et al. 2008) while other report its presence 
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(Crosby D, Poole AW. 2003; Murugappan S et al. 2004); although is now well established 
that mouse platelet express PKCε (Pears CJ et al. 2008), functional data are still 
contradictory. 
In platelets from PKCε null mouse, Pears et al showed a marked inhibition of aggregation 
and dense granule secretion in response to GPVI agonists but no significant functional 
change in response to ADP (Pears CJ et al. 2008). At the opposite, recently Bynagari-
Settipalli et al (Bynagari-Settipalli YS et al. 2012) showed an increase in ADP-induced 
aggregation and secretion in platelets from PKCε null mice. Indeed, signaling through 
GPVI suggests a role for PKCε in the initial steps of thrombus formation in mouse 
platelets. 
On these basis, functional role of novel PKC, and in particular PKCε, in human platelet 
still needs large studies to be clearly defined.  
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2. AIM OF THE THESIS  
Among PKC family, PKCε and PKCδ could be considered the yin and yang of novel 
PKCs, because of their antithetical role in many cellular mechanisms such as proliferation, 
apoptosis, tumor growth and cardioprotection. 
 
In this contest, my research aimed to investigate a possible opposite role of these two PKC 
isoforms in unexplored fields such as (i) circulating platelets function and properties and 
(ii) regulation of in-vitro human megakaryocytopoiesis and platelet production. Data 
available from the literature suggest that 
In mature platelets circulating in the pheripheral blood, the levels of expression of PKCε 
are opposed to those of PKCδ. In fact, it is well documented that human platelets express 
PKCδ and that this isoform is involved in platelet activation, degranulation and 
aggregation. 
By contrast, PKCε expression is still a subject of debate. Anyway, the majority of data 
shows that, on the contrary to PKCδ, it is absent in human platelets, while it is expressed in 
murine platelets where it plays a proaggregant function. 
 
On these basis, during the first period of my doctoral fellowship, I focused my research on 
PKCε expression in human platelets, exploring whether its levels could be associated to 
platelet hyper-reactivity and related diseases (i.e. acute myocardial infarction), in order to 
clarify PKCε role in platelet function. 
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Since platelets are enucleated cell fragments, their trascriptome and proteome reflect that 
of megakaryocytes they derive from. Indeed, PKCε expression in mature human platelets 
(i.e. virtually absent) is consistent with its down-modulation during the later phases of 
megakaryocytopoiesis. Although it is well established that PKCδ is present in human 
platelets regulating their function, little is known about its expression during 
megakaryocytopoiesis  
Given this background, during the second period of my doctoral fellowship I sought to 
demonstrate whether PKCδ expression in human platelets could be specific, and timely 
modulated during megakaryocyte differentiation, similarly to what described for PKCε. 
Therefore I studied PKCδ expression and function using in vitro model of human 
megakaryocytopoiesis. 
Finally, given the growing interest of the scientific community on ameliorating  in vitro 
platelet production for transfusion purposes, I studied whether the modulation of 
PKCε/PKCδ balance could affect platelet production in vitro 
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PART I: 
PKCε IN PLATELETS FUNCTION 
 
To investigate PKCε expression in human platelets of peripheral blood and its function on 
platelet reactivity, I performed ex vivo tests on platelets obtained from healthy donors and 
patients affected by acute myocardial infarction and stable coronary artery disease. 
 
3.1.1 PATIENTS 
Three groups of subjects were studied: 1) twenty-four acute myocardial infarction patients 
(MI) with an ST-segment elevation; 2) twenty-four patients with newly-diagnosed stable 
CAD (sCAD) and 3) twenty-four healthy subjects (HD). Patients were enrolled at the 
Cardiology Division of the Azienda Ospedaliero-Universitaria of Parma after written 
informed consent was obtained and the study was performed according to the Declaration 
of Helsinski. The protocol was approved by the unique Local Ethical Committee of the 
Ospedale Maggiore of Parma and University of Parma. Blood collection from MI patients 
was accomplished within 12 hours from the acute event (in most cases within 3– 4 hours) 
and before any invasive procedure or pharmacological treatment was performed. Previous 
antiplatelet therapy was an exclusion criteria in all groups.  
Fifty ml of citrate anti-coagulated blood samples were taken from patients and controls 
(collected in Vacutainers, 3.8% sodium citrate final concentration; BD Vacutainer, Becton 
Dickinson, San Diego, CA) for subsequent analyses.  
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3.1.2 PLATELET ACTIVATION 
Aliquots of whole blood samples were stained with anti-CD62p monoclonal antibody 
(mAb) as a marker of platelet activation and a-granule release and analyzed by flow 
cytometry (Solinas E et al. 2009; Carubbi C et al. 2014). Briefly, 1:100 PBS-diluted whole 
blood was incubated with the mAb CD62p-FITC (anti P-selectin, Pharmingen Becton 
Dickinson, San Diego, CA) in the presence of incremental doses of ADP (0; 1,25; 2,5; 5 
mM). After 20 min at room temperature, 400 ml of 2% buffered paraformaldehyde was 
added for fixation. 
Analysis of the samples was performed by an Epics XL flow cytometer (Beckman Coulter, 
Fullerton, CA) and the Expo ADC software (Beckman Coulter). In some experiments, the 
absolute number of surface antigens expressed/cell was calculated. To this purpose, the 
flow cytometer was calibrated with a set of standardized beads (DAKO, Glostrup, 
Denmark) each with a known amount of fluorochrome (either FITC or PE) expressed in 
units of MESF (Molecules of Equivalent Soluble Fluorescein). Thus, a standard curve was 
constructed by plotting MESF values for the beads against the median channel in which 
the peak was displayed. 
 
3.1.3 PLATELET PURIFICATION 
All the remaining blood samples were centrifuged at 160 g for 20 minutes at room 
temperature (RT), to obtain platelet rich plasma (PRP). Platelets were then purified by 
negative separation using magnetic beads coated with anti-CD45 antibodies (Dyna- 
beadsH, Invitrogen, Carlsbad, CA), to deplete nucleated cells. Briefly, PRP were stained 
with the magnetic beads-coated mAb anti-CD45 for 20 min at RT on a rotator. Purified 
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platelets were washed 3 times in PBS/BSA solution, counted, tested for purity by anti-
CD41 staining and flow cytometry analysis (only samples where CD41+ cells .98% were 
used), and finally processed for RNA extraction. 
 
3.1.4 RNA ISOLATION 
Higly purified platelets were treated with an appropriate amount of TRIzolTM (Invitrogen) 
for cell lysis and RNA extraction, following the manufacturer’s protocol. Briefly, chloro- 
form was added to TRIzolTM-treated samples and centrifuged at 12.000 g for 15 min at 
4°C. The acqueous phase, containing RNA, was transferred in a new tube and added with 
an equal volume of isopropanol. After incubation, the samples were centrifuged at 12.000g 
for 15 min at 4°C, to obtain RNA pellets that were washed and resumed in DEPC-treated 
water for quantification by spectrophotometer. 
 
3.1.5 AMPLIFICATION OF RNA FOR PKCε GENE EXPRESSION ANALYSIS 
The isolated RNA was both positively and negatively tested for cell population purity by 
Reverse-Transcription PCR (RT-PCR). A standard set of primers was used to test platelet 
RNA (amplification of CD41) or contaminant cells RNA (amplification of CD45 for 
nucleated cells).  
Platelet RNA purification was followed by reverse transcription and RT-PCR to yield 
complementary DNA (cDNA). From the cDNA sample, cRNA was synthesized by in vitro 
transcription (IVT), and then analyzed for PKCε gene expression. Briefly, 1 μg total RNA 
was reverse transcribed with MMV reverse transcriptase and subjected to PCR 
amplification to detect CD41, CD45 and PKCε cDNA.  
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PCR were performed under the following reaction conditions: 95 ºC for 30 sec, 56 ºC for 
30 sec, 72 ºC for 30 sec and a final extension at 72 ºC for 5 min. We used 35 cycles of 
amplification. The sequences of primers used for PCR were: CD41: 5'-GCAAT GTCGA 
GGGCT TTGAG-3' (sense) and 5'-GGCTG TTCTT GCTCC GTATC-3' (antisense); 
CD45: 5'-GGAAG TGCTG CAATG TGTCA TT-3' (sense) and 5'-CTTGA CATGC 
ATACT ATTAT CTGAT GTCA-3' (antisense); PKCε: 5’-CAATG GCCTT CTTAA 
GATCA AAA-3’ (sense) and  5’-CCTGA GAGATC GATGATC ACATAC-3’ 
(antisense). Primers used for PKCε RT-PCR amplify exon 1 and exon 2 sequences 
flanking the first intronic sequence of the gene, which is 190,000 bp. 
 
3.1.6 QUANTITATIVE ANALYSIS FOR PKCε GENE EXPRESSION BY REAL-TIME 
PCR  
Equal quantities of RNA for each sample were retro-transcribed with Malone Murine 
Leukemia Virus Reverse Transcriptase (Promega, Madison WI, USA) according to 
manufacturer’instructions. Two µl of 1:1 cDNA dilution were used to perform real-time 
PCR with GoTaq® qPCR master mix (Promega) and 200 nM of each primer in Applied 
Biosystems StepOne real-time machine (Applied Biosystems, Carlsbad, CA). Each 
reaction was performed in triplicate and mean Ct values were considered for quantitation. 
Relative gene expression was analysed using comparative Ct experiment software subset 
following manufacturer’s instructions.  
The sequences of primers used for PCR were: CD41: 5'-GCAAT GTCGA GGGCT 
TTGAG-3' (sense) and 5'-GGCTG TTCTT GCTCC GTATC-3' (antisense); CD45: 5'-
GGAAG TGCTG CAATG TGTCA TT-3' (sense) and 5'-CTTGA CATGC ATACT 
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ATTAT CTGAT GTCA-3' (antisense); PKCε: 5’-CACCA TCCAG TTTGA GGAGC-3’ 
(sense) and  5’-CGACC CTGAG   AGATC GATGA -3’ (antisense). 
 
3.1.7 PROTEIN EXTRACTION AND WESTERN BLOT 
Total proteins were extracted from 1 ml (450x103/μl) of purified platelets. Briefly, 1 ml of 
isolated platelets from each sample was collected and centrifuged at 1700 rpm for 10 min. 
The pellets were then suspended in a cell lysis buffer (50mM Tris-HCl, pH 7.4; 1% NP-40; 
0.25% sodium deoxycholate; 150 mM NaCl; 1 mM EDTA; 1 mM PMSF; 1 mM Na3VO4; 
1 mM NaF) supplemented with fresh protease inhibitors and protein concentration was 
determined using BCATM protein assay kit (Pierce, Rockford, IL). Fifty µg of proteins 
from each sample were then migrated in 5% SDS-acrylamide gels and blotted onto 
nitrocellulose filters.  
Blotted filters were blocked and incubated with specific primary antibodies diluted as 
described in maunfacturers’ protocols. Specifically, rabbit polyclonal anti-PKCε (Upstate, 
Lake Placid, NY) and  mAb anti-β-actin (Sigma, Saint Luis, MO) were diluted 1:5000. 
Filters were washed and further incubated for 1.5 hours at room temperature with 1:5000 
peroxidase-conjugated anti-rabbit or with 1:2000 peroxidase-conjugated anti-mouse IgG 
(Pierce) in the primary antibody working solution at RT. Specific reactions were revealed 
with the ECL Supersignal West Pico Chemiluminescent Substrate detection system 
(Pierce). 
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3.1.8 PKCε PROTEIN EXPRESSION IN PLATELETS BY FLOW CYTOMETRY 
Aliquots of PRP samples were stained with: i) anti-CD41a monoclonal antibody (mAb), as 
a marker of platelet population; ii) Thyazole Orange (TO), to identify reticulated platelets; 
iii) rabbit anti-PKCε monoclonal antibody, to test the presence of PKCε protein; and 
analyzed by flow cytometry. Briefly, 200 µl of PRP were washed and treated with 
IntraPrepTM Permeabilization Reagent (Immunotech, Marseille, France), following 
manufacturer’s protocol. One-hundred µl of Reagent 1 (fixation reagent) were added to the 
samples. After 15 min of incubation at room temperature, samples were washed and 
incubated with 100 µl of Reagent 2 (permeabilization reagent), 10 µl CD41a-Cy5 (Becton 
Dickinson, San Diego, CA) and 1 µl of affinity purified rabbit anti-PKCε Ab (Novus 
Biologicals, Littelton, CO); negative control was incubated with 100 µl of Reagent 2,  10 
µl isotype-matched IgG-Cy5 (Immunotech) and 1 µl of an isotype-matched Ab (rabbit 
IgG, Sigma) for 45 min at room temperature in the dark. After a washing step, 1 µl of 
affinity purified goat anti-rabbit-PE Ab (Beckman Coulter) was added and the samples 
were incubated for 45 min at room temperature in the dark. Finally, the samples were 
washed and a solution10 ng/ml of TO (Sigma) was added, in the presence or absence of 10 
mg/ml RNAsi (negative control), and incubated for 30 min at room temperature in the dark 
and analysed by Flow Cytometry. Working  dilutions of all reagents were previously 
determined with serial dilution tests. All samples were analysed on an FC500 flow 
cytometer (Beckman Coulter). 
 
3.1.9 PLATELET TRASFECTION WITH PKCε PROTEIN 
Human recombinant PKCε (rhPKCε; GenWay Biotech, San Diego, CA) was transfected 
into purified platelets using Proteojuice protein transfection reagent (Novagen, Podenzano, 
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Italy), according to manufacturer’s protocols. For each transfection, 1ml of PRP was 
centrifuged at 1800 rpm for 7 min, the supernatant was removed and pellets were washed 
with serum-free medium. Subsequently, samples were centrifuged at  1800 rpm for 7 min 
and medium was completely removed. The transfection mixture was prepared as follows: 
25μl of serum-free medium were added to 1µg of PKCε protein (or nothing, as negative 
control) and 1,25 μl of ProteoJuice protein transfection reagent. After 20 min of incubation 
at room temperature, 225 µl of serum-free medium were added to the transfection mixture. 
Finally, the platelet samples were incubated with the mix at 37°C, 5% CO2  for 3,5 hours. 
After transfection, the samples were washed twice with serum-free medium to remove 
excess protein. 
In some experiments, transfected and control platelets were re-added to platelet-deprived 
whole blood and aliquots were then used for platelet activation analysis by flow cytometry, 
as described above.  
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3.1.10 PLATELET ADHESION ANALYSIS IN SHEAR RATE SYSTEM 
Isolated PRP was treated for rhPKCε transfection, as described above. The procedures to 
prepare a washed erythrocyte suspensions have been described previously in detail 
(Mazzucato M et al. 2004). PRP containing 2-8 x108 loaded platelets/ml was mixed with 
washed erythrocytes, to obtain a suspension with hematocrit of 42-45%, and apyrase 
(grade III; 142 ATPase U/mg of protein; Sigma) was added at the final concentration of 5 
ATPase U/ml. The mixture was centrifuged at 1000 g for 15 min, the supernatant was 
discarded and the cell pellet was suspended in plasma. Suspensions of acid-insoluble 
fibrillar type I collagen from bovine achille tendon (Sigma) in 0.5M acetic acid (pH 2.8) 
were prepared as previously described (Folie BJ et al 1988) and two hundred microliters  
was used to coat glass coverslips for 60 minutes at 22-25°C in a humidified box. After 
coating, coverslips were washed with PBS and kept in a moist environment until 
assembled in a modified Hele-Shaw flow chamber (Savage B et al 1998). The flow 
chamber was positioned on the stage of an inverted microscope equipped with 
epifluorescent illumination (Diaphot-TMD; Nikon Instech, Shinagawaku, Japan), an 
intensified CCD videocamera (C-2400-87; Hamamatsu Photonics, Shizuoka, Japan), and 
appropriate filters. The total area of an optical field corresponded to approximately 0.007 
mm2. Blood cells were aspirated through the chamber with a syringe pump (Harvard 
Apparatus, Hollistone, MA) at a flow rate calculated to obtain the desired wall shear rate at 
the inlet. Platelet adhesion was measured using blood containing 10 µM mepacrine to 
render platelets fluorescent.  
Three negative controls were run for each sample: i) untreated platelets; ii) platelets treated 
with a PKCε traslocation inhibitor peptide (Merck KgaA, Darmstadt, Germany) added to 
the trasfection mixture (1ug of inhibitor peptide) with or, iii) without rhPKCε.  
Experiments were recorded in real time on videotape at the rate of 25 frames/s, which 
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resulted in a time resolution of 0.04 s. Selected video sequences were also digitized in real 
time using a Matrox-Digisuite board (Matrox Graphics Inc., Dorval, Quebec, Canada).  
Single frame images were captured from videotapes after an initial blood perfusion for 3 
minutes on the different substrates. A threshold was applied to distinguish platelets from 
the background and the area occupied by all platelets in an image was measured using 
MicroImage (image-processing software; Tesi-Imaging srl, Venice, Italy).  
 
3.1.11 STATISTICAL ANALYSIS  
The variables were compared between the three groups of patients using One Way Anova 
and Bonferroni t-test for multiple comparisons. Where indicated the variables were 
compared using Mann-Whitney test. T-test for independent or correlated samples was used 
to compare some indicated data. All the results are expressed as means plus or minus SD. 
Chi-square analysis of contingency tables were used for PKCε mRNA expression analysis 
of frequency comparison in the three groups. All the statistical tests were performed at the 
0.05 p-value. 
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PART II: 
PKCδ/ε BALANCE IN HUMAN THROMBOPOIESIS 
 
To investigate PKCδ expression during megakaryocytopoiesis and platelet production and 
the role of PKCδ/ε balance in human thrombopoiesis, I used an in vitro model of MKs 
differentiation from human CD34+ haematopoietic stem cells. 
 
3.2.1 CD34
+
 CELL ISOLATION AND CELL CULTURE 
Primary CD34
+
 cells were isolated from peripheral blood of healthy donors and primary 
myelofibrosis (PMF) patients. Samples were collected in sodium citrate tubes after written 
informed consent and approval by the Ethical Committee of Parma University Hospital  
(according to the Helsinki declaration of 2004 and informed consent was obtained from the 
donors). Primary CD34
+
 cells were purified by immunomagnetic positive selection using 
the CD34
+
-cell isolation Kit (Milteny Biotech, Gladbach, Germany) in the magnetic field 
of autoMACS Pro Separator (Milteny Biotech), according to the manufacturer’s protocol. 
Purity of CD34
+
 cells was immediately checked by a R-phycoerythrin (RPE)-conjugated 
anti-CD34 mAb (Immunotech, Beckman Coulter, Miami, FL) and flow cytometry; only 
samples exceeding 95% purity were used for subsequent experiments. 
Purified human CD34
+
 cells were cultured up to 14 days, at an optimal cell density of 
1x106 cells/ml, in serum free X-vivo medium (Lonza Group, Switzerland) supplemented 
with 200 ng/ml of recombinant human thrombopoietin (TPO), 50 ng/ml of recombinant 
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human stem cell factor (SCF) and 3 ng/ml of recombinant human interleukin-3 (IL-3) 
(Peprotech, London, UK) renewed every 3 days. 
 
3.2.2 shRNA CELL INFECTION 
For shRNA-based gene silencing, pLKO.1 lentiviral vector encoding short hairpin RNAs 
(shRNA) against human PKCdelta (transcription variant 1, NM_212539 and transcription 
variant 2, NM_006254; shPKCdelta) were obtained from Open-Biosystem (Thermo Fisher 
Scientific Inc, Waltham, MA USA). As control (shCT), we used the MISSION pLKO.1-
puro Non-Target shRNA Control Plasmid, containing an shRNA insert that does not target 
any known genes from any species (Sigma-Aldrich, St. Louis, MO, USA). shRNA 
expressing viruses were produced in 293TL cells according to standard protocols. Cells 
were infected at Day 8 of TPO-culture and then cultured in the presence of puromycin, to 
select infected, puromycin-resistant cells.  
At Day 14 of culture, infected MKs were analysed for morphological evaluation by light 
microscopy and an aliquots from each cultures were collected for flow cytometry and 
western blot analysis. 
 
3.2.3 PHARMACOLOGICAL INHIBITION AND ACTIVATION OF PKCδ AND PKCε 
PKCδ activity was modulated by the δV1-1 (SFNSYELGSL) and by ψδRACK ( 
MRAAEDPM) peptides coniugated to TAT47-57 (CYGRKKRRQRRR) by a cysteine 
disulfide bound (synthesized by Selleckchem, Huston, TX, U.S.A). PKCε activity was 
modulated by the εV1-2 (CEAVSLKPT) and by ψεRACK (CHDAPIGYD) peptides 
coniugated to TAT47-57 (CYGRKKRRQRRR) by a cysteine disulfide bound (synthesized 
  Materials & Methods 
 97 
by AnaSpec Inc, Fremont, CA, U.S.A). TAT47-57 (CYGRKKRRQRRR) peptide was used 
as control (synthesized by AnaSpec Inc, Fremont, CA, U.S.A). Briefly, δV1-1 and εV1-2 
are peptides corresponding to the least conserved sequences between isozymes within the 
C2 domain that selectively inhibit the corresponding isozyme preventing PKC 
translocation and substrate phosphorylation.  Instead ψδRACK and ψεRACK are PKC 
allosteric activator derived from the C2 region sequence, implicated in auto inhibitory 
intramolecular interactions (Mochly-Rosen D, Nature reviews 2012; 11: 937-957). 
MK cultures of primary CD34+ cells were splitted into four treatments from day 8: i) cells 
treated with 1µM ψδRACK and 1µM εV1-2  (ψδRACK / εV1-2); ii) cells treated with 
1µM δV1-1  and 1µM ψεRACK (δV1-1 / ψεRACK); iii) cells treated with 2µM TAT47-57 
as control (TAT47-57); iiii) untreated cells (Untreated). Peptides were renewed every 48 
hours, cells were cultured up to 13 days and then collected for further analysis.  
 
3.2.4 MORPHOLOGICAL EVALUATION OF MKs DIFFERENTIATION  
Cell plates at 14 days of culture were analysed using Leica DM IL phase contrast 
microscope (40X/0.5NA) and images were obtained by Leica ICC50 HD camera (Leica 
Microsystems, Wetzlar, Germany). 
Percentage of megakaryocytes extending proplatelets and cell diameter were determined 
using ImageJ software analizing 100 cells for each treatment from at least four independent 
experiments.  
 
 
3.2.5 FLOW CYTOMETRIC ANALYSIS 
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Flow cytometry was used to analyse the viability and the ploidy of the differentiating cell 
populations at day 14 of culture.  
Cell culture viability was assessed by propidium iodide (PI) (Sigma-Aldrich) staining, 
briefly aliquot of cells were incubated with  2,5 ug/ml of PI in PBS for 15 minutes in dark 
at room temperature and then analysed by flow cytometry.  
For ploidy analysis, aliquots of cells were permealized with 70% ethanol overnight at 4°C, 
washed with PBS and incubated in PBS containing 50 μg/ml PI and 100 μg/ml RNAse-A 
(Sigma-Aldrich) for 15 minutes in dark at room temperature before flow cytometry 
analysis. CD34
+
 cells at day 0 were used as marker for the identification of the diploid 
(2N) peak. 
Finally, to quantify the platelet production in culture, fixed volumes of the culture 
supernatants were collected, incubated with anti-CD41-RPE and calcein AM (to exclude 
fragments; Sigma-Aldrich) and added to a fixed volume of calibration beads (DAKO, 
Agilent Techonolgies, Santa Clara CA, U.S.A) at known concentration. Both the platelets 
and beads populations were simultaneously identified in flow cytometry on the Forward 
Scatter (FS) vs logarithmic Side Scatter (SS) dot plot. The absolute platelets count was 
performed on the gated CD41+/Calcein AM+ platelet population (Gobbi G. 2009; Nurden 
P. Blood 2010). 
Analysis of the samples was performed by an FC500 flow cytometer (Beckman Coulter) 
and the Expo ADC software (Beckman Coulter).  
 
 
3.2.6 PROTEIN EXPRESSION ANALYSIS 
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Cultured cells were counted and 1.5 x 106 cells were collected on Days 0, 3, 6, 9, 14 for 
healthy donors and on day 14 for PMF and ITP patients. Cells were washed in PBS and 
centrifuged at 200g for 10 min. Pellets were resuspended in a cell lysis buffer (50mM Tris-
HCl, pH 7.4; 1% NP-40; 0.25% sodium deoxycholate; 150 mM NaCl; 1 mM EDTA; 1 
mM PMSF; 1 mM Na3VO4; 1 mM NaF) supplemented with fresh protease inhibitors and 
protein concentration was determined using BCATM protein assay kit (Pierce, Thermo 
Scientific). Twenty five μg of proteins from each sample were ran on 4-20% SDS-
acrylamide gels (Biorad), blotted onto nitrocellulose membranes, blocked and incubated 
with specific primary antibodies diluted as described in maunfacturers’ protocols. 
Specifically, mouse monoclonal anti-PKCdelta antibody (BD Pharmingen, Cat. #610397) 
was diluted 1:500, rabbit polyclonal anti-PKCepsilon antibody (Merk Millipore, Cat.# 06-
991) was diluted 1:1000,  rabbit polyclonal anti-Bax antibody and rabbit polyclonal anti-
Bcl-xL antibody (Cell Signaling Technology, Inc. Lake Placid, NY, Cat. # 2772 and Cat. # 
2762) were diluted 1:500 and 1:1000 respectively and monoclonal anti-GAPDH antibody 
(Merk Millipore, Cat. # MAB374), 1:5000 dilution was used as protein loading control.  
Membranes were washed and incubated for 1.5 hours at room temperature with 1:5000 
peroxidase-conjugated anti-rabbit (Pierce, Thermo Fisher Scientific Inc) or with 1:2000 
peroxidase-conjugated anti-mouse IgG  (Sigma-Aldrich) at room temperature and resolved 
by ECL Supersignal West Pico Chemiluminescent Substrate detection system (Pierce, 
Thermo Fisher Scientific Inc). Protein densitometric analyses from western blot assays 
were performed by using the Image J software system, normalized for GAPDH expression 
levels.  
 
3.2.7 STATISTICAL ANALYSIS 
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Statistical analysis were performed by using t-Test to compare two samples, Anova and 
Tukey Tests for multiple comparisons. 
 
  
 
 
 
 
 
 
4. RESULTS 
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PART I: 
PKCε IN PLATELETS FUNCTION 
 
PKCε is virtually absent in human platelets and its expression is precisely regulated during 
human megakaryocytic differentiation. In mice platelets, PKCε shows a proaggregant 
function. Platelet hyperactivation play crucial roles in the pathophysiology of thrombosis 
and myocardial infarction (MI). On these basis, I hypothesized that platelets from 
myocardial infarction patients might ectopically express PKCε with a pathophysiological 
role in the disease. 
 
4.1.1 MI PATIENTS CARRY HYPER-RESPONSIVE PLATELETS 
It is well known that patients with acute coronary syndromes carry hyper-responsive 
platelets (Smitherman TC et al.1981; Langford EJ et al. 1996) and show systemic platelet 
activation (Langford EJ et al.1996; Theroux P, Fuster V. 1998; Vaitkus PT et al.1995; 
Hamm CW et al. 1987; Dorn GW, 2nd, 1990). Therefore, I first studied the activation state 
of platelets and their sensitivity to agonistic stimuli in a randomly selected sub-group of 
patients. In agreement with the current literature, I found that platelets from MI patients 
express significantly higher surface levels of p-selectin than those from sCAD patients and 
healthy donors (Fig. 4.1.1A). Moreover, in MI patients CD62p expression was induced at 
significantly higher levels by sub-optimal doses of ADP (Fig. 4.1.1B). 
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Figure 4.1.1.Platelet activation in MI patients. Panel A: Left. Flow cytometric analysis of platelet CD62p 
surface expression in patients with MI, sCAD and healthy donors. Cells were stained with specific mAb anti 
P-selectin, as described in Materials and Methods. Ten patients were analyzed for each group. Right. 
Quantification of CD62p expression on the surface of platelets from MI, sCAD and HD. Absolute numbers 
of surface antigens expressed/cell (MESF). (Anova and Bonferroni t-test; * P<0.05 MI vs HD; no significant 
differences were found between stableCAD and HD). Panel B: Platelet surface expression of CD62p in MI 
(●), sCAD (▲) and HD (○) patients in the presence of increasing doses of ADP. Left  panel shows the 
percentage of positive cells. Right panel shows the absolute numbers of surface antigens expressed/cell 
(MESF). Data from 7 patients of each group are expressed as means ± S.D. (Anova and Bonferroni t-test; * 
P<0.05 MI vs HD; no significant differences were found between stable CAD and HD). 
 
4.1.2 PLATELETS FROM MI PATIENTS CONTAIN mRNA FOR PKCε AND 
EXPRESS PKCε PROTEIN 
Since PKCε is finely modulated during megakaryocytopoiesis (Gobbi G et al. 2007) and it 
is known to increase the response of mouse platelets to GPVI-mediated activation (Pears 
CJ et al. 2008), I reasoned that it could be a good candidate to account for the hyper-
responsiveness of platelets from MI patients. Therefore, I extracted total mRNA from 
highly purified platelets and studied the expression of mRNA for PKCε by RT-PCR. The 
absence of nucleated cells contamination in the isolated platelet population was assessed 
by RT-PCR for CD45 expression (Fig. 4.1.2A). Moreover, given the dimensions (190 Kb) 
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of the first intronic sequence of the PKCε gene and the positioning of the primers I used 
for PKCε RT-PCR, I could reasonably exclude the presence of PKCε pre-mRNA in 
platelets. In agreement with previous data (Pears CJ et al. 2008), expression of PKCε 
mRNA was found at low frequency both in platelets from normal subjects and sCAD 
patients. On the contrary, platelets from the majority of MI patients (21 out of 24; 87.5%) 
had a clear-cut expression of PKCε mRNA (Fig. 4.1.2B, C), as confirmed also by qPCR 
(Fig. 4.1.2D).  
 
Figure 4.1.2 Platelets from MI patients contain mRNA for PKCε. Panel A: Representative RT-PCR analysis 
of CD41 and CD45 expression in MI, sCAD and healthy donor platelets. Equal amounts of total cDNA were 
amplified by PCR to detect the indicated mRNA expression. CD45 is not expressed in isolated platelets, 
indicating the absence of nucleated cell contaminants. Panel B: Representative RT-PCR analysis of PKCε 
expression in MI, sCAD and healthy donor platelets. Equal amounts of total cDNA were amplified by PCR 
to detect PKCε mRNA. Platelets from MI patients express PKCε. PC: positive control; NC: negative 
control. Panel C: Analysis of PKCε RNA expression in MI, sCAD and HD platelets. The samples positive to 
PKCε mRNA expression in MI, sCAD and HD were respectively 21, 8, 3 out of 72 (24 each group) (Chi-
square test: p = 0.0001 MI vs HD; p = 0.0001 MI vs sCAD; no significant differences were found between 
sCAD and HD). Panel D: Quantitative analysis of PKCε mRNA expression by real-time PCR. Equal 
amounts of total cDNA were amplified by PCR. The expression level of PKCε mRNA in each patient was 
compared with the mean expression in the HD group. Data from 10 patients of each group are shown (Mann 
Whitney test: p = 0.001 MI vs HD; p = 0.009 MI vs sCAD; no significant differences were found between 
sCAD and HD). 
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I consequently studied the expression levels of PKCε protein by Western Blot selecting 
PKCε mRNA-positive patients from each group (10 patients from the MI group; 5 patients 
from the sCAD group; 3 subjects from HD group). As expected, accordingly with qPCR 
results, PKCε expression in MI patients was about three fold greater then sCAD and 
healthy subjects (Fig. 4.1.3A, B). 
 
Figure 4.1.3 . Platelets from MI patients express PKCε protein. Panel A: A representative Western blot assay 
for the detection of total PKCε protein expression in platelets from PKCε mRNA-positive MI , sCAD and 
HD. β-Actin was assayed for protein loading. Panel B: Densitometric analysis of PKCε protein expression 
normalized against β-actin in PKCε mRNA-positive MI , sCAD  and HD platelets. Data are expressed as 
means ± S.D. (Anova and Bonferroni t-test; * P<0.05 MI vs HD; # P<0.05 MI vs sCAD; no significant 
differences were found between sCAD and HD). Panel C: PKCε protein expression in mature and immature 
platelets from healty donors (HD) and MI patients. Cells were simultaneously labelled with Thyazole 
Orange (TO) -to visualize the immature platelet fraction (IPF) - and anti-PKCε mAb, and analyzed by flow 
cytometry. Three populations were identified within the CD41+ cell subset: PKCε negative reticulated 
platelets (TO+EPS-);  PKCε positive reticulated platelets (TO+EPS+); PKCε positive mature platelets (TO-
EPS+); (Data from 3 patients/group,  expressed as means ± S.D.  t-Test ** P<0.001; * P<0.05). 
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To test if this ‘‘ectopic’’ expression of PKCε in the platelets from MI patients could be 
attributed to the immature platelet fraction, I analysed by flow cytometry the population of 
reticulated platelets from MI patients and HD. As reported in Figure 4.1.3C, the percentage 
of platelets from MI patients expressing PKCε protein was significantly increased both in 
mature (TO-EPS+) and immature (reticulated) (TO+EPS+) platelet fractions, as compared 
to HD. More specifically, the ratio between PKCε positive platelet subsets from MI vs HD 
subjects was 2.9±0.73 in mature platelets (TO-EPS+) and 2.17±1.44 in immature platelets 
(TO+EPS+) (p = 0.48, ns). 
 
4.1.3 PLATELETS FROM MI PATIENTS DURING FOLLOW UP BECAME 
NEGATIVE FOR PKCε mRNA 
To test whether the expression of PKCε in MI was transient or stable, 11 randomly 
selected MI patients positive for platelet PKCε mRNA expression were re-called between 
day 15 and day 30 from the acute episode and the platelets were tested again for PKCε 
expression. All platelet samples were found negative for PKCε mRNA expression as soon 
as 15 days from the acute MI episode (not shown). 
 
4.1.4 PKCε-EXPRESSING PLATELETS ARE HYPER-RESPONSIVE 
To study the correlation between PKCε expression and platelet activation, I compared the 
p-selectin (CD62p) cell surface expression in PKCε positive vs PKCε negative platelets in 
all the analysed groups (Fig. 4.1.4A). The general trend is a significant higher p-selectin 
expression in PKCε positive cells. Subsequently, I tested the platelet reactivity to the 
stimulation with sub-optimal doses of ADP. As expected, both PKCε negative and positive 
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platelets were activated, as compared to controls (resting), but the positive cells were 
significantly more reactive than the negative (Fig. 4.1.4B). 
 
Figure 4.1.4 PKCε protein expression in platelets correlates with their activation levels. Panel A: Flow 
cytometric analysis of platelet CD62p surface expression in patients with MI, sCAD, healthy donor and in 
all the sample (ALL), on the basis of PKCε expression. Cells were stained with specific mAb anti P-selectin 
(CD62p). Seven patients were analyzed for each group (MI: 2 PKCε negative and 5 PKCε positive samples; 
sCAD: 4 PKCε negative and 3 PKCε positive samples; HD: 4 PKCε negative and 3 PKCε positive samples). 
Data is expressed as mean ± S.D (Anova and Bonferroni t-test). Panel B: Flow cytometric analysis of 
CD62p surface expression in PKCε negative and positive platelets. Cells were treated with ADP and 
compared with untreated platelets (resting). Ten patients were analyzed for each group. Data is expressed as 
mean ± S.D (Anova and Bonferroni t-test). 
 
4.1.5 PKCε-OVEREXPRESSING PLATELETS ARE HYPER-RESPONSIVE AND 
SHOW ENHANCED ADHESION TO COLLAGEN 
To study the functional role of PKCε in platelets, I subsequently forced its expression in 
platelets from normal healthy donors in vitro mimicking the in vivo situation. rhPKCε 
protein was therefore successfully transfected in healthy donor platelets (thus originally 
negative for PKCε expression) (Fig. 4.1.5A). Subsequently, PKCε+ platelets were 
functionally assayed for ADP-induced activation and shear stress adhesion, using mock-
transfected normal platelets as negative controls. 
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First, PKCε+ normal platelets and control platelets were treated with minimal doses of 
ADP (0.3 mM) and analyzed for CD62p surface expression by flow cytometry. There were 
no significant differences in the surface expression of CD62p between PKCε+ normal 
platelets and control platelets in the absence of ADP stimulation. On the contrary, PKCε+ 
platelets treated with 0.3 mM ADP express significantly higher levels of CD62p than 
control platelets (Fig. 4.1.5B). 
 
Figure 4.1.5 PKCε protein transfection in normal platelets induces hyper-responsiveness to ADP-mediated 
activation. Panel A. Western blot detection of total PKCε protein expression in transfected platelets. Healthy 
donor platelets were incubated with ProteoJuice medium in the presence or absence (negative control) of 
recombinant PKCε (rhPKCε). K562 cells were used as positive control. β-Actin was assayed for protein 
loading. Panel B: The expression of CD62p on the surface of activated platelets was compared to the 
expression of CD62p on resting platelets. rhPKCε-transfected platelets were significantly more reactive than 
activated control platelets. Left  panel shows the percentage of positive cells. Right panel shows the absolute 
numbers of surface antigens expressed/cell (MESF). Data from 5 independent experiments (each symbol is 
related to one experiment) are expressed as means ± S.D. (Anova and Bonferroni t-test; * P<0.05 activated 
platelets vs resting platelets – II vs I and IV vs III; # P<0.05 rhPKCε-transfected platelets vs activated control 
platelets – IV vs II). 
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Second, I studied the adhesion to collagen-coated surfaces of PKCε-overexpressing normal 
platelets under controlled physiological low (600 sec21) or high (1500 sec21) shear rates. 
Adhesion to collagen at 1500 sec21 was significantly increased in normal platelets over-
expressing PKCε, particularly after 3 minutes testing, (Fig. 4.1.6). Although hampered by a 
high variability, adhesion at low shear rate also showed a trend to increase. Adhesion of 
PKCε-transfected platelets treated with the PKCε inhibitor was similar to that of untreated 
platelets, demonstrating the specificity of the observed enhancement. 
 
Figure 4.1.6. PKCε enhances platelet adhesion to fibrillar type I collagen under flow conditions. rhPKCε-
transfected and control platelets were reconstituted in whole blood, previously deprived from PRP, and 
tested for their adhesion capacity under flow. Mepacrine-loaded platelets (5-7x10
8
/ml) and washed 
erythrocytes (hematocrit 42-45%) suspended in plasma, were perfused for 3 minutes over immobilized 
fibrillar type I collagen. Surface coverage was measured on an area of 0.07 mm
2
 after 3 minutes of perfusion 
at 600 s
-1
 or 1500 s
-1
 and is shown as mean ± 95% confidence intervals of at least 3 separate experiments. 
Results are shown relative to the values observed in untreated blood cell suspensions (control) (Anova and 
Bonferroni t-test; * p< 0.01). Representative single-frame images of each surface are also shown.  
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PART II: 
PKCδ/ε BALANCE IN HUMAN THROMBOPOIESIS 
 
It has been demonstrated that in human megakaryocytic differentiation, PKCε modulates 
MK maturation and platelets release and that it is down-regulated in the final step of 
megakaryocytpoiesis, in agreement with its absence in human platelets. It’s also well 
known that PKCδ mediate contrasting and even opposing effects as compared to PKCε in 
several non-hematopoietic models. On these basis I hypothesized that, during the process 
of platelets production, PKCδ might has an opposite role than PKCε and that the PKCδ/ε 
balance could be a key factor for human thrombopoiesis. 
 
4.2.1 PKCδ/PKCε and Bax/Bcl-xL EXPRESSION LEVELS ARE DIFFERENTLY 
MODULATED DURING MK DIFFERENTIATION 
In agreement with previous studies in human megakaryocyte cultures (Gobbi G et al. 
2007), PKCε protein expression increases during the early phases of MK differentiation, 
declining on the final steps of this process. On the contrary, human PKCδ rises at the 
beginning of megakaryocytopoiesis, remaining highly expressed throughout the entire 
maturation process (Fig. 4.2.1A, B).  
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Besides, both Bcl-xL and Bax expressions are significantly modulated in differentiating 
MKs, with a kinetic similar to PKCε and PKCδ respectively (Fig. 4.2.1A, C).
 
Figure 4.2.1 PKCdelta/PKCepsilon and Bax/Bcl-xL expression levels are differently modulated during MK 
differentiation. Panel A: Western blot detection of PKC delta, PKCepsilon, Bax, Bcl-xL protein expression 
in MK cultures. GAPDH was monitored for protein loading. Panel B: Relative PKC delta and PKCepsilon 
protein expression during megakaryocytic differentiation human CD34
+
 cells normalized for GAPDH 
expression levels. Panel C: Relative Bax and Bcl-xL protein expression during megakaryocytic 
differentiation human CD34
+
 cells normalized for GAPDH expression levels. Densitometric measurements 
of Western blots from 3 replicates were performed by ImageJ software (means ± SD; * p < 0.05 Anova and 
Tukey tests).  
 
4.2.2 PKCδ DOWN-REGULATION REVERSES THE NORMAL EXPRESSION OF 
Bcl-xL AND Bax 
It has been previously demonstrated that during late phases of MK differentiation the 
PKCε-forced expression induces Bcl-xL up-regulation (Gobbi G et al. 2007). Based on 
PKCδ-specific shRNA data, I sought to determine whether PKCδ expression is necessary 
for regulating normal levels of Bcl-xL and Bax expression at the end of 
megakaryocytopoiesis. Therefore, I used recombinant lentiviral vectors to introduce and 
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stably express shRNA molecules that specifically target PKCδ into MK differentiating 
cells at Day 8 of culture. Analysis of megakaryocyte cultures at Day 14 (Day 5 post-
infection) revealed that the abrogation of PKCδ was specific, as it did not modify the 
expression of PKCε (Fig. 4.2.2A, B). However, the selective down-regulation of PKCδ 
dramatically reduces Bax and boosts Bcl-xL expression (Fig. 4.2.2A, B). The 
densitometric analysis (panel B) of western blot assays clearly indicate a significant 
modulation of the tested proteins only in the presence of PKCδ-specific shRNA 
(shPKCdelta), as compared to the samples infected with control shRNA (shCT), which are 
fully similar to those uninfected.  
 
Figure 4.2.2 . PKCdelta down-regulation reverses the normal expression of Bcl-xL and Bax. Panel A: 
Western blot detection of PKCdelta, PKCepsilon, Bax, Bcl-xL in human MK uninfected (UN) or infected 
with PKCdelta-specific shRNA (shPKCdelta), and Non-Target shRNA control (shCT). GAPDH was 
monitored for protein loading. Panel B: Densitometric analysis of proteins expression, normalized for 
GAPDH expression levels, were performed using ImageJ software. Densitometric measurements of Western 
blots from 4 replicates (means ± one SD; *p<0.05 ANOVA and Tukey Tests). 
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4.2.3 PKCδ DOWN-REGULATION IMPAIRS MK DIFFERENTIATION AND 
PLATELET FORMATION 
Analysis of puromycin-selected MK cultures at Day 5 post-infection revealed that 
abrogation of PKCδ affected MK differentiation (Fig. 4.2.3). Indeed, PKCδ-specific 
shRNA (shPKCdelta) infected cells resulted more viable (Fig. 4.2.3A), smaller (Fig. 
4.2.3B) and less polyploid (Fig. 4.2.3 C, D), as compared to controls (Uninfected and 
shCT).  
 
Figure 4.2.3 PKCdelta down-regualtion impairs MK differentiation. Panel A: Cell viability analysis of 
puromycin- selected MK cultures at day 5 post-infection. Percentage of PI negative cells from 3 replicates 
(cells data express as percentage of shCT; means ± one SD;  *p<0.05 ANOVA and Tukey tests). Panel B: 
Analysis of size distribution within uninfected MK and puromycin- selected MK cultures at day 5 post-
infection. Percentage of cells with a given diameter range of 3 replicates. (mean ± one SD; *p<0.05 
shPKCdelta vs Uninfected, #p<0.05 shPKCdelta vs shCT, ANOVA and Tukey tests). Panel C: 
Representative histogram of  cell ploidy analysis of puromycin- selected MK cultures at day 5 post-
infection. Panel D: Percentage of puromycin- selected MK cultures at day 5 post-infection with a DNA 
content >4N from 3 replicates (cells data express as arbitrary unit of shCT; means ± one SD;  *p<0.05 
ANOVA and Tukey tests). 
 
Although few residual branched protrusion could still be observed, proPLTs generated by 
shPKCdelta-infected cells were characterized by few abortive branches and virtual absence 
of the discoid structures (Fig. 4.2.4A). On the contrary, shCT-infected MKs, as well as 
uninfected samples, were characterized by the presence of platelet formation (Fig. 4.2.4A).  
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Moreover, I observed a greater than 50% reduction in platelet numbers in cultures where I 
introduced PKCdelta shRNA (Fig. 4.2.4B). 
 
Figure 4.2.4. PKCdelta down-regualtion impairs pro-platelets formation. Panel A: representative images of 
pro-platelet forming MK of uninfected, infected with specific shRNA for PKCdelta (shPKCdelta) or control 
(shCT) at day 5 post-infection. Panel B: Analysis of platelet production of uninfected, infected with specific 
shRNA for PKCdelta (shPKCdelta) or control (shCT) at day 5 post-infection from 5 replicates. (data were 
normalized for shCT, means ± one SD;  *p<0.05 ANOVA and Tukey tests). 
 
4.2.4 PKCδ/PKCε BALANCE REGULATES HUMAN THROMBOPOIESIS 
In this in vitro MK-differentiating model, PKCδ and PKCε showed different kinetics, 
reaching opposite expression levels at Day 14 of colture (Fig. 4.2.5). 
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Figure 4.2.5. A schematic rapresentation of PKCδ and PKCε protein expression levels during MK 
differentiation 
 
I hypothesized that the normal expression or even the rate of these two PKC isoforms 
could be pivotal for usual megakaryocytopoiesis and platelet production. In order to test 
this speculation, CD34
+
 cells were isolated from peripheral blood of patients affected by 
primary myelofibrosis (PMF) a disease characterized by abnormal platelet production. 
Isolated cells were cultured up to Day 14 in the presence of TPO and then collected for 
further western blot analysis (Fig. 4.2.6A). As shown in Figure 4.2.6B, TPO-treated cells 
from PMF were characterized by an abnormal expression of PKCδ and PKCε, as well as 
Bcl-xL and Bax. Indeed, accordingly with previous data (Masselli E et al. In Press), in 
PMF samples the expression levels of PKCε and Bcl-xL were considerable higher than in 
healty donors (HD) (Fig. 4.2.6B). As expected, the expression levels of PKCδ and Bax 
were almost halved in PMF, as compared to HD (Fig 4.2.6B). 
Afterwards, HD-derived MK differentiating cells were treated with specific PKCε and 
PKCδ activatory or inhibitory peptides at Day 8 and then cultured for further 5 days.  As 
assumed, the simultaneous inhibition of PKCδ and activation of PKCε significantly 
reduced the amount of platelets released in colture (Fig. 4.2.6.C).  
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Figure 4.2.6. An imbalance between PKCδ and PKCε  reduces platelet release. Panel A: Western blot 
detection of PKCdelta, PKCepsilon, Bax, Bcl-xL in human MK at day 13 of differentiation of Healthy 
donor (HD) and PMF patient. GAPDH was monitored for protein loading. Panel B: Densitometric analysis 
of proteins expression, normalized for GAPDH expression levels, were performed using ImageJ software. 
Densitometric measurements of Western blots from 4 replicates (means ± one SD; *p<0.05 t-Tests) Panel C: 
Analysis of platelet production of  untreated (UNTR), treated with TAT47-57 peptide (TAT47-57), PKCdelta 
inhibitor peptide, PKCepsilon activator peptide alone (δV1-1 and ψεRACK respectively) or in combination 
(δV1-1/ ψεRACK) cultures, at day 5 post treatment. Data were expressed as arbitrary unit of control (TAT47-
57) from at least 3 independent experiments. (means ± one SD; ANOVA and Tukey Tests). 
 
Conversely, the concurrent pharmacological PKCδ activation and PKCε inhibition clearly 
demonstrated the possibility to potentiate platelet production, increasing proplatelet 
formation and platelet delivery, as shows in figure 4.2.7. As a matter of fact, the 
combination of PKCδ-activator peptide and PKCε-inhibitor peptide, was able to boost both 
the percentage of MK producing proplatelet formation (Fig. 4.2.7 A) and the number of 
released platelet in culture media (Fig. 4.2.7. B), as compared to controls. 
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Collectively, thee data show that platelet production can be in vitro forced by modulating 
PKCδ/PKCε expression and function. 
 
Figure 4.2.7. The amount of platelet production can be revised by modulating PKCepsilon/PKCdelta 
expression. Panel A: Analysis of pro-platelet producing megakaryocytes of untreated (UNTR),  treated with 
TAT47-57 peptide (TAT47-57), PKCdelta activator peptide, PKCepsilon inhibitor peptide alone (ψδRACK and 
εV1-2  respectively) or in combination (ψδRACK / εV1-2 ) cultures, at day 5 post treatment. Data were 
expressed as % of megakaryocyte extending pro-platelet analizing 100cells for each treatment from at least 
3 independent experiments. (means ± one SD; ANOVA and Tukey Tests).Panel B: Analysis of platelet 
production of  untreated (UNTR),  treated with TAT47-57 peptide (TAT47-57), PKCdelta activator peptide, 
PKCepsilon inhibitor peptide alone (ψδRACK and εV1-2  respectively) or in combination (ψδRACK / εV1-
2 ) cultures, at day 5 post treatment. Data were expressed as arbitrary unit of control (TAT47-57) from at least 
3 independent experiments. (means ± one SD; ANOVA and Tukey Tests).
  
 
 
 
 
 
 
5. DISCUSSION 
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Protein kinase C (PKC) is a family of serine-threonine kinase involved in many 
cellular functions, including cell death, proliferation and differentiation (Corbalán-García 
S et al. 2006). 
In particular PKCδ and PKCε are two isoforms with opposing roles in many cell 
models. PKCε is largely considered as an oncogene because of its anti-apoptotic and pro-
proliferation functions (Newton PM and Messing RO 2011), conversely PKCδ generally 
slows proliferation, induces cell cycle arrest and apoptosis (Steinberg SF 2004). In the 
heart, they are among the most widley expressed PKC isozymes and they play an 
antithetical role in the ischemic-reperfusion preconditioning process (i.e.: enhancing role 
forPKCε and inhibiting role for  PKCδ (Chen L et al. 2001). Moreover, the importance of 
these two PKC isoforms in pathological conditions has been proven by clinical trials 
based on specific PKCε and PKCδ inhibitor peptides (Mochly-Rosen D et al. 2011). 
Platelets are the smallest blood cells with a primary physiological role in hemostasis. They 
are produced by megakaryocytes as anucleated cells that contain proteins and mRNA 
derived from megakaryocyte. Platelets retain also the protein synthesis machinery, 
therefore, platelet mRNAs can be efficiently translated during platelet life, during around 
10 days. 
PKCs have been established as important regulators of several platelet functions. The 
physiological expression of the different PKC isoforms varies significantly in mature 
platelets, with relevant differences in humans and mice. 
Concerning novel PKC isoforms, it has been demonstrated that PKCδ is expressed in 
human platelets and regulates the activation response to GPVI agonists and adhesion to 
collagen (Hamm CW et al. 1987). This behavior of PKCδ in humans is similar to the one 
described for PKCε in mice, where it plays a relevant role in the activatory signaling 
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cascade emanating from the GPVI receptor (Pears CJ et al. 2008). On the other hand, 
PKCε expression and function in human platelets is still very controversial (Crosby D and 
Poole AW. 2003; Muruggapan S et al. 2004; Beunsuceso S et al. 2005; Pears CJ et al. 
2008). 
The results of my research showed that the majority of HD-derived platelets did not 
express PKCε. This is in agreement with previous data (Gobbi G et al. 2007) describing 
the down-modulation of PKCε expression in in vitro human megakaryocytopoiesis from 
day 6 onward of TPO-driven MK differentiation of CD34 precursors. 
Platelets play a central role in the genesis and propagation of atherothrombosisis 
and the development of platelet thrombus is a critical, final phase in myocardial infarction.  
I demonstrated that in human platelets, PKCε is selectively de novo expressed in 
myocardial infarction, but not in stable coronary artery disease patients, and its expression 
returns negative after 15 days of follow-up after the acute event. Additionally, by 
functional experiments, I demonstrated that PKCε-transfected normal human platelets 
enhance their adhesion properties to collagen-coated surfaces under physiologically high 
shear forces. Myocardial infarction patients express PKCε mRNA at significantly higher 
frequency than healthy donors and stable coronary artery disease. Considering the 
dimensions of the first intronic sequence of the PKCε gene, that would virtually preclude 
the persistence of a potential PKCε pre-mRNA in the platelet, my findings suggest that 
platelet generations produced before the acute event of myocardial infarction might retain 
PKCε-mRNA that is not down-regulated during terminal MK differentiation. An 
alternative explanation would be an anticipated release of platelets, before physiological 
PKCε down-modulation. This possibility is however unlikely, as PKCε down-modulation 
takes place around day 6 of in vitro MK differentiation, that would be too early. Besides, 
the analysis conducted on the reticulated platelets of some myocardial infarction patients, 
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randomly selected from the recruited cohort, did not show any difference in terms of 
PKCε expression as compared to mature platelets, excluding the possibility that the 
appearance of PKCε positive platelets in myocardial infarction patients could be 
selectively ascribed to newly formed platelets.   
These results suggest that the ectopic expression of PKCε in platelets could be used as a 
marker of probability to anticipate the acute event in patients at risk. 
Since many pathological conditions depend on an abnormal platelet function, the 
study of molecular mechanisms involved in platelet activation and thrombus formation, 
has always been a matter of great interest. On the other hand, many diseases are related to 
abnormal platelet production. 
Thrombocytopenia is a major clinical problem encountered across a number of 
conditions, including immune thrombocytopenic purpura, myelodysplastic syndromes, 
chemotherapy, aplastic anaemia, human immunodeficiency, virus infection, complications 
during pregnancy and delivery, and surgery. Patients with a low platelets number are at 
increased risk of spontaneous bleeding or hemorrhage and, to prevent them, they are 
treated with platelet transfusion. However the use of apheresis-equivalent units derived 
from human donors, shows several limitations and challenges with platelet preparation 
and storage technologies , such as clinically significant immunogenicity, associated risk of 
sepsis and inventory shortages due to high and 5-days shelf life (Thon JN et al. 2014). 
On these basis, two strategies are possible: i) to potentiate an in vitro platelet 
producing system to obtain platelets for infusion and ii) to develop pharmacological 
treatments able to modulate in vivo megakaryocytopoiesis and platelet production. 
Therefore, a deeper understanding of molecular mechanisms that control 
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megakaryocytopoiesis is a key element to regulate in vitro and in vivo platelet production 
for clinical applications. 
PKCε is involved in human and mouse megakaryocytopoiesis.  
In human CD34
+
-derived MKs, PKCε is down-modulated in the later phases of 
differentiation and its forced overexpression reduces cell polyploidization and platelet 
production via Bcl-xL up-regulation (Gobbi G et al 2007). 
Using the same model, I found that, conversely to PKCε levels, PKCδ is constantly 
expressed and its forced down-modulation results in reduced MKs differentiation and 
platelet release via Bcl-xL up-regulation and Bax down-modulation. 
The importance of PKCε and PKCδ balance in human thrombopoiesis is additionally 
proven by my findings in pathological conditions, ie. myeloproliferative disorders. 
Primary myelofibrosis is a chronic myeloproliferative neoplasm characterized by bone 
marrow hyperplastic MKs with an impaired capacity to generate proplatelets in vitro. 
Interestingly, I found that PMF-CD34
+
-derived megakaryocytes show an imbalance 
between PKCδ/ PKCε expression, with an increase in PKCε levels- in agreement with our 
more recent data (Masselli et al. In press) – and a decrease in PKCδ levels, than those 
from healthy subjects. Moreover, these expression levels of PKCs are associated with 
similar imbalance between their down-stream effectors Bcl-xL and Bax, respectively. 
Finally, using a pharmacological inhibitor and activator of PKCδ and PKCε function, I 
obtained a modulation of in vitro platelet production. The concomitant PKCδ inhibition 
and PKCε activation reduces platelet release; conversely, PKCδ activation associated with 
PKCε inhibition clearly demonstrates the possibility to potentiate platelet production.  
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Collectively, these data suggest that novel PKCs i) should be adequately expressed in 
human circulating platelets and PKCε ectopic expression could be associated to 
cardiovascular deseases, suggesting its possible use as a risk marker; ii) have a crucial role 
during normal human megakaryocytopoiesis and platelet production, through a 
mechanism  involving apoptotic pathway (specifically Bcl-xL and Bax); iii) might be 
modulated, as protein expression levels, during in vitro megakaryocytopoiesis and by 
modifying their rate is possible to revise platelet production, suggesting future strategy for 
platelet diseases therapy and infusion-aimed platelet expansion. 
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